USE OF DRUGS WITH ANTICHOLINERGIC PROPERTIES AND FACTORS AFFECTING COGNITION IN PATIENTS WITH MILD DEMENTIA

Institutt for Helsefag
Master i Helsevitenskap, Selvvalgt Fordypning
Masteroppgave (50 studiepoeng)

Jolanda Jonas

Veiledere:
Ingelin Testad
Ragnhild Djønne Østerhus

31.05.2016
## Nordisk tittel:
Bruk av antikolinerge legemidler og faktorer assosiert med kognitiv svikt blant pasienter med mild dementia

## Engelsk tittel:
Use of drugs with anticholinergic properties and factors affecting cognition in patients with mild dementia

## EMNEORD/STIKKORD:
Anticholinergic drugs, dementia, cognitive impairment, home-dwelling

## Antall sider: 95 sider

## Stavanger, 31. mai 2016
This thesis is made as a completion of the master education in Health Science at University of Stavanger. Writing this thesis has been hard and challenging, but I have learned a lot in the process. Many people have contributed in this thesis and helped me in several ways, and I would like to take this opportunity to express my gratitude.

I would like to thank my main supervisor, Postdoc Ingelin Testad, for her positive encouragement and continual help as well as her excellent educational skills during this work.

PhD-candidate Ragnhild Djønne Østerhus is my co-supervisor, and I am sincerely thankful for her giving me excellent guidance, availability and quick response to my questions as well as her dear involvement and effort that have been essential for this thesis.

Special thanks to Professor Dag Aarsland in Centre for Age-Related Medicine (SESAM) Stavanger for contributing his valuable expertise and constructive comments. I wish to thank Ingvild Dalen of the Research Department at the Stavanger University Hospital for her kind assistance with the statistical analysis. I would also like to thank all the people in SESAM Stavanger who have helped and supported me in the work on this thesis.

I am grateful to my loving parents, family and friends, who put up with me and support me all along the way.

Finally, I would like to dedicate this thesis to my dear husband, Teddy, for his unfailing support, love and continuously belief in me. This thesis would not have been possible without his help. He is always there for me, and keeps me motivated if I ever feel down. As always, to my very wonderful children, Stefan and Konrad, who have shown great understanding during this work, and give me so much joy, love, support and terrific times. Thank you for being such huge blessings in my life.
# Table of Contents

## Part 1  Master Thesis

Table of Contents..................................................................................................................4
List of Abbreviations..............................................................................................................6
Abstract..................................................................................................................................7
1.  Introduction ..................................................................................................................8
   1.1  Background ...........................................................................................................8
   1.2  Previous Research ..............................................................................................10
   1.3  Objectives of the study........................................................................................12
   1.4  Research Questions and Hypotheses ..................................................................13
       1.4.1.  Main question ..........................................................................................13
       1.4.2.  Additional questions ..............................................................................13
       1.4.3.  Hypothesis ..............................................................................................13
   1.5.  Limitations ...........................................................................................................13
2.  Theoretical Perspectives .................................................................................................14
   2.1.  Dementia ...........................................................................................................14
   2.2.  Anticholinergic Drugs ......................................................................................15
   2.3.  Age-related pharmacokinetics and pharmacodynamics changes ...................16
3.  Methods ..........................................................................................................................22
   3.1.  Research Design ...............................................................................................22
   3.2.  Data Collection ...................................................................................................22
   3.3.  Inclusion Criteria ...............................................................................................23
   3.4.  Exclusion Criteria ..............................................................................................23
   3.5.  Assessments .......................................................................................................24
       3.5.1.  Dementia Diagnosis ..............................................................................24
       3.5.2.  Clinical Assessment ...............................................................................24
       3.5.3.  Measurement of Anticholinergic Potency and Anticholinergic Load ....26
   3.6.  Statistical Analysis ..............................................................................................26
4.  Results .............................................................................................................................29
   4.1.  Baseline Characteristics ....................................................................................29
   4.2.  Use of anticholinergic drugs ..........................................................................30
   4.3.  Predictors of cognitive decline .........................................................................31
Part 2 Article

Abstract.................................................................................................................56
Introduction ...........................................................................................................57
Methods ..................................................................................................................58
  Subjects..............................................................................................................58
  Ethical Issues.....................................................................................................58
  Dementia Diagnosis ..........................................................................................59
  Clinical Assessment............................................................................................59
  Measurement of Anticholinergic Drug Load.....................................................60
  Statistical Analysis..............................................................................................60
Results....................................................................................................................61
Discussion ..............................................................................................................63
Acknowledgment ................................................................................................67
Conflicts of Interest ...............................................................................................67
References ..............................................................................................................68
Attachment ............................................................................................................71
  Tables and Figures.............................................................................................71
  Author Guidelines..............................................................................................75
LIST OF ABBREVIATIONS

CDR : Clinical Dementia Rating
MMSE : Mini-Mental State Examination
ADE : Adverse Drug Event
START : Screening Tool to Alert doctors to the Right Treatment
STOPP : Screening Tool of Older Persons’ potentially inappropriate
Prescriptions
DLB : Dementia with Lewy-bodies
PDD : Parkinson’s Disease Dementia
LBD : Lewy Body Dementia
AD : Alzheimer’s Dementia
CIRS : Cumulative Illness Rating Scale
BBB : Blood-brain barrier
Abstract

Background: Elderly people, particularly those with dementia, are at high risk of adverse anticholinergic drug effects. Despite the well-recognized potential for cognitive decline with anticholinergic agents, their use continues even among patients with dementia. Objectives: to estimate the prevalence of drugs with anticholinergic drug effects and its impact on cognitive decline over time in home-dwelling people with dementia in Norway. Methods: Referrals to five outpatient clinics in geriatric medicine, old age psychiatry and neurology in Western Norway during 2005-2013 were included. Cognitive decline was assessed for up to 5 years using Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE). Cox regression was applied to model the cognitive decline. Results: Nearly 60% patients received at least one drug with anticholinergic property whereas almost 12% were taking drugs with well-known anticholinergic activity. However, the findings did not support the hypothesis that use of drugs with anticholinergic properties increases the risk of worsening cognitive decline among home-dwelling people with dementia. Moreover, the study showed that patients with Lewy body dementia and lower cognition at baseline predicted faster cognitive decline.

The thesis is part of the Master Study in Health Sciences at University of Stavanger, Norway. The thesis is divided into two parts; the first part is supported by theoretical framework, and the second part is an article, which is to be sent for publication.
1. INTRODUCTION

1.1 Background

Improvements in health care in the past century have contributed to people living longer and healthier lives. As a result, there is an increase in the number of people with dementia. Cognitive impairment is one of the main health problems facing elderly people in the new era. Some studies suggest that delaying the deterioration of cognitive function in elderly for a few years would result in a significant improvement on physical and economical burden related to the condition (Derousen, 2002).

Dementia is a clinical syndrome characterized by an inevitable progressive cognitive decline, which affects memory, thinking, behavior and ability to perform everyday activities. It represents a major public health challenge for many high-income countries and one of the major causes of disability and dependency among older people worldwide. (Prince et al., 2012; World Health Organization, 2012).

The World Health Organization has calculated that more than 47 million people worldwide are living with dementia in 2015 and that the number is expected to grow at an alarming rate. It is estimated that the number will increase to 76.5 million and rise to more than triple by 2050 (World Health Organization, 2016). In Norway, the number of people with dementia is approximately 78,000 in 2015, and by 2060 it is expected to triple. The risk of dementia increases with age and the incidence of dementia is estimated to be around 10,000 new people with dementia per year (Engedal & Haugen, 2009; Vossius et al., 2015).

Older people have often multiple chronic diseases, which frequently lead to polypharmacy and therefore increase the risk of inappropriate medications. Inappropriate medications are an important aspect of suboptimal prescribing in the elderly. Certain medications may exacerbate the progression of
dementia, and can make treating dementia even more challenging (Bunn et al., 2014; Schubert et al., 2006). Age-related changes in pharmacokinetics and pharmacodynamics, together with comorbidity and polypharmacy, increase risk for adverse drug reactions in dementia patients, which sequentially are cause of significant health challenges and costs (Corsonello, Pedone, & Incalzi, 2010).

Anticholinergic drugs are used therapeutically to treat medical conditions such as urinary incontinence, irritable bowel syndrome, diarrhea, seasonal allergies and Parkinson’s disease (Feinberg, 1993; Gray et al., 2015). Peripheral adverse effects include dry mouth, dry eyes, constipation, blurred vision, pupil dilatation, and increased heart rate. Central side effects include impaired concentration, confusion, hallucinations, delirium, memory impairment and falls (Bell et al., 2012; Gerretsen P, 2011; Ness, Hoth, Barnett, Shorr, & Kaboli, 2006).

Although drugs with anticholinergic effects are considered as potentially inappropriate medications, anticholinergic medications are frequently prescribed to older adults for diverse conditions (Beuscart, Dupont, Defebvre, & Puisieux, 2014; Sura, Carnahan, Chen, & Aparasu, 2013). The prevalence of anticholinergic drug use in older people varies enormously. Previous studies have reported that 40-60% of patients with dementia used at least one anticholinergic medication and that 10-20% used drugs with clinically significant anticholinergic effects (Bhat-tacharya R., 2011; Sura et al., 2013). The prevalence is even higher in nursing home (Chatterjee, Mehta, Sherer, & Aparasu, 2010; Sura et al., 2013). These utilization rates are concerning because patients with dementia are more sensitive to anticholinergic effect due to impaired cholinergic neurotransmission and an associated decrease in cognitive function (Bell et al., 2012; Carriere et al., 2009; Sura et al., 2013).

As anticholinergic drugs are widely used, patients may be subjected to a high anticholinergic load. High anticholinergic drug load have been suggested to result in adverse events such as cognitive impairment and delirium (Bell et al.,
2012; Gray et al., 2015; Mate et al., 2015), hospitalizations (Kalisch Ellett, Pratt, Ramsay, Barratt, & Roughhead, 2014) and mortality (Fox et al., 2011). These adverse events can have consequences for daily functioning, quality of life, caregiver burden and health-related costs. Although health professionals are well aware of the potential adverse effects of drugs with marked anticholinergic activity, most did not consider the cumulative anticholinergic load when prescribing for the elderly (Bell et al., 2012; Tune, 2001).

Despite the potentially enormous public health implications, only few studies have evaluated the prevalence of anticholinergic use and its association with worsening cognitive decline over time in home-dwelling people with mild dementia in Norway. Such information is important for the management of people with dementia, as avoiding drugs that accelerate cognitive decline may improve the quality of life of these patients.

1.2 Previous Research

As the population is steadily growing older, comorbidity is frequently present. Consequently, many patients are exposed to polypharmacy, which is associated with frequent negative health outcomes caused by drug-related problems (Viktil, Blix, Moger, & Reikvam, 2007). The findings reported by Gandhi et al. (2003) found that adverse events related to drugs occur frequently in primary care, and many are preventable. Most of the preventable events were due to prescribing errors (an inappropriate choice of drugs, drug interaction, or drug allergy). In addition, the patients in their study had significantly higher number of medications. The most frequent type of adverse drug events and the most frequent preventable or ameliorable events were those related to the central nervous system, e.g. antidepressant (Gandhi et al., 2003).

It is well known that anticholinergic medications should be avoided in older adults due to increased sensitivity towards adverse effects. In spite of the recommendation, medications with anticholinergic properties are commonly used in the elderly, including patients with dementia. It has been reported
previously that 40-60% of dementia patients use at least one anticholinergic medication and the prevalence was even higher in nursing homes (Bhattacharya R., 2011; Chatterjee et al., 2010; Mate et al., 2015; Sura et al., 2013). Over one in ten patients with dementia received medications with high anticholinergic potency. Nevertheless, the largest use of anticholinergic medications (>60%) was made by low potency anticholinergic drugs (Chatterjee et al., 2010; Mate et al., 2015; Sura et al., 2013).

Numerous studies have observed an association between anticholinergic drug load and the risk of developing cognitive impairment, but their results are conflicting (Cai, Campbell, Khan, Callahan, & Boustani, 2013; Carriere et al., 2009; Ehrt, Broich, Larsen, Ballard, & Aarsland, 2010; Gray et al., 2015). A recent longitudinal study found that higher cumulative anticholinergic use was associated with an increased risk of dementia. However, this study focused only on high potency anticholinergic drugs based on pharmacologic properties, and the results may be specific to drugs that are commonly used in the USA (Gray et al., 2015).

A cohort study from France observed an association between anticholinergic drug use and an increased risk of developing dementia and cognitive decline. Discontinuing anticholinergic drug treatment was associated with reduced risk of developing dementia (Carriere et al., 2009). In line with other studies, Cai et al. (2013) found an association between anticholinergic load and the risk of developing cognitive impairment. Such an association required both high anticholinergic load and 2 to 3 months of continuous exposure to a high burden. However, such a high exposure of anticholinergic load did not increase the probability of dementia diagnosis (Cai et al., 2013). Detailed assessment of the anticholinergic drug load in these studies examined only the well-known anticholinergic effects, but did not include other drugs associated with such effects (Cai et al., 2013; Carriere et al., 2009; Gray et al., 2015).

A community-based cohort study from Norway found that drugs with anticholinergic properties affected the rate of cognitive decline in patients with
Parkinson’s disease. However, this study has some limitations. There was a high attrition due to death because of the long test-retest interval, and some survival could not provide adequate scores on tests such as Mini Mental State Examination (MMSE). Moreover, MMSE is not a very sensitive measure of cognitive impairment in Parkinson’s disease (Ehrt et al., 2010).

To my knowledge, just few longitudinal studies have shown no significant association between anticholinergic drug use and cognitive impairment in dementia. Bottiggi et al. (2006) discovered no significant differences between anticholinergic drug users and the non-users, after adjusting for age and education. Yet the results did lead to an accelerated rate of decline in scanning, visuomotor tracking, and components of exclusive functioning. However, the authors themselves considered their results as being preliminary, because their study was a non-randomized prospective study with unequal groups. In addition, the study did not have access to determine the continuous exposure to anticholinergic drugs (Bottiggi et al., 2006).

Ancelin et al. (2006) found that anticholinergic drug intake was associated with a non-degenerative cognitive impairment but suggested that it was unlikely linked to an increased risk of dementia. The results may due to the small sample size and because most of the drug users were classified as mild cognitive impairment. (Ancelin et al., 2006).

In addition, evidences suggest that taking more anticholinergic medications is associated with greater risk of hospitalization for confusion or dementia (Kalisch Ellett et al., 2014) and increased mortality (Fox et al., 2011).

1.3 Objectives of the study

The aim of the study was to estimate the prevalence of anticholinergic drug use and its impact on cognitive decline over time in home-dwelling people with mild dementia in Norway.
1.4 Research Questions and Hypotheses

1.4.1. Main question
How is the use of drugs with anticholinergic properties and its impact on cognitive decline over time in home-dwelling patients with mild dementia in Western Norway?

1.4.2. Additional questions
1. What is the prevalence of anticholinergic drugs use in home-dwelling patients with mild dementia in Western Norway?
2. What are the association between use of drugs with anticholinergic properties and the decline of cognition among home-dwelling people with mild dementia?
3. Does use of anticholinergic drugs increase the risk of increased cognitive impairment?

1.4.3. Hypothesis
The hypothesis is that use of drugs with anticholinergic properties is associated with increased risk of worse cognitive decline among home-dwelling patients with mild dementia in Western Norway.

1.5. Limitations
As a consequence of the defined study objectives, the following limitations apply:

- The term and definitions presented in chapter 2 of this thesis are limited to what is considered necessary in order to analyze and discuss the selected adverse events. The selection is not intended to be completed.
- The thesis is limited to the impact of use of drugs with anticholinergic properties to cognitive decline in home-dwelling patients.
2. THEORETICAL PERSPECTIVES

This chapter provides relevant theoretical backgrounds of dementia, anticholinergic drugs and age-related changes in elderly. Thus, it presents concept of patient safety and relation between adverse drug events and inappropriate prescribing.

2.1. Dementia

Dementia is a clinical syndrome of acquired cognitive impairment produced by brain dysfunction and although dementia is more common in older adults, it is not a normal consequence of aging (Engedal & Haugen, 2009; Quinn, 2013). Dementia leads to impairment in short- and long term memory, associated with impairment in abstract thinking, impaired judgment, and other disturbances of higher cortical function, or personality changes. They will often have psychological changes as well, for example, become frustrated or irritable, depression, anxious, inappropriate behavior, paranoid, agitation and hallucinations. The disturbance is severe enough to interfere significantly with work or usual social activities or relationships with others (Engedal & Haugen, 2009; McKeel, Burns, Meuser, & Morris, 2007).

The most common causes of dementia are Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, and frontotemporal dementia (Engedal & Haugen, 2009; Quinn, 2013). Some neurological diseases, such as Parkinson disease and Huntington disease, can cause dementia because of their effects on brain tissue. Dementia may also cause by vitamin deficiencies, long-term alcohol abuse and AIDS. Although many form of dementias, such as vitamin deficiencies and drugs-related dementia are reversible, but most forms are irreversible (Engedal & Haugen, 2009).
2.2. Anticholinergic Drugs

Anticholinergics drugs are a class of drugs that binds to muscarinic receptors in the parasympathetic system and thereby blocking the action of the neurotransmitter acetylcholine in the brain. Acetylcholine plays an important role in cognition, such as short-term memory and learning. Acetylcholine-producing cells in the basal forebrain are damaged in the early stages of dementia, which may contribute to the memory impairment, which is an early symptom of the disease (Becker, 2012; Micheau & Marighetto, 2011).

Some anticholinergic drugs are used therapeutically to treat medical conditions such as urinary incontinence, irritable bowel syndrome, diarrhea, seasonal allergies and Parkinson’s disease. Others, such as antihistamines, antidepressants and antipsychotics, have significant unintended anticholinergic effects that are not the primary therapeutic activity (Feinberg, 1993; Gray et al., 2015).

Anticholinergic adverse effects can cause both peripheral and central side effects. Peripheral adverse effects include dry mouth, dry eyes, constipation, blurred vision, pupil dilatation, and increased heart rate. These peripheral adverse effects can lead to a plethora of medical complications, such as respiratory problems to myocardial infarction. Central side effects include impaired concentration, confusion, hallucinations, delirium, memory impairment and falls (Bell et al., 2012; Gerretsen P, 2011; Ness et al., 2006). Hence, drugs with anticholinergic effects are often considered as potentially inappropriate medications (Beuscart et al., 2014; Sura et al., 2013). The adverse effects may be marginalized as temporary, minor side effects of a medication or a result of patient’s preexisting condition. Eliminating or reducing the doses of medications known to have anticholinergic potencies, may sometimes improve the anticholinergic adverse effects (Lieberman, 2004).
2.3. **Age-related pharmacokinetics and pharmacodynamics changes**

A wide spectrum of changes occurs in the human body with age, which can affect how the body reacts to drugs. That is why drug therapy in elderly may produce different and unexpected responses, compared with younger patients (Greenblatt, Harmatz, & Shader, 1991; Hämmerlein, Derendorf, & Lowenthal, 1998).

Age-related changes in pharmacokinetics mainly affect distribution, metabolism and excretion of the drug and to a lesser extent the drug absorption. The changes are mainly due to the loss of functional capacity of several organs and the reduced efficacy of homeostatic mechanisms. Principally hepatic drug clearance of several drugs decreases with aging due to reduced blood flow and hepatocyte mass. Renal function also decreases with aging, mainly because of sclerotic changes in the glomeruli. Moreover, as a result of decreased muscle mass, older patients frequently have reduced glomerular filtration rate despite normal serum creatinine, and such an obscured renal insufficiency may impact significantly the clearance of hydrosoluble drugs (Corsonello et al., 2010).

Pharmacodynamics describes how the drugs affects the body and gives knowledge on how the drug and its receptor interact. Changed receptor density, the homeostatic regulation, as well as age, gender, genetics and diseases are all variables that can affect the pharmacodynamics. There is a general trend of greater pharmacodynamics sensitivity in the elderly; however, this is not universal, and these age-related changes must be investigated separately for each individual drug, or at least relatively homogeneous groups of drugs (Bowie & Slattum, 2007).

Changes in pharmacodynamics are well documented in the central nervous system (CNS). Furthermore, older people frequently show an exaggerated response to CNS-active drugs. This is in part due to an underlying age-related
decline in CNS function and in part due to increased sensitivity for some CNS-drugs such as benzodiazepines, anesthetics, and opioids because of altered neurotransmitters and receptors density (Corsonello et al., 2010).

As age increased, the permeability of the blood-brain barrier (BBB) may also increase. Alterations in BBB permeability leading to higher brain concentrations and may result in poor tolerability by aged persons. Therefore, drugs with anticholinergic effects normally not passing the BBB now may penetrate it. As a result, BBB disruption may contribute to an acute worsening of global cognitive functioning with decreased attention and tend to be more severe for a given dose of drugs (Zeevi, Pachter, McCullough, Wolfson, & Kuchel, 2010).

2.4. Patient Safety

2.4.1. Definition

World Health Organization (2015) defined patient safety as

*Freedom from accidental injuries during the course of medical care; activities to avoid, prevent, or correct adverse outcomes, which may result from the delivery of health care.*

*The identification, analysis and management of patient-related risks and incidents, in order to make patient care safer and minimize harm to patients.*

Adverse events are defined as an undesirable clinical outcome resulted from some aspect of diagnosis or therapy, not underlying disease process, that leads to disability, prolonged hospital stay or function decline (Aase, 2010, 2015; Brennan et al., 1991). Several studies revealed that adverse events were the most prevalent preventable harms.

*Adverse drug event is any injury, large or small, occurring during the patient’s drug therapy and resulting either from appropriate care, or from*
unsuitable or suboptimal care. It includes the adverse drug reactions during normal use of the medicine, and any harm secondary to a medication error, both errors of omission or commission (Council of Europe, 2005).

There are two types of adverse drug events: those caused by errors and those that occur despite proper usage. Adverse drug reactions include all non-preventable adverse drug events that contribute to injury, but no error (Council of Europe, 2005).

2.4.2. Adverse Drug Events (ADEs)

As part of the Hippocratic Oath, "Primum non nocere", the Latin phrase that means "First, do no harm" is a basis for ethics taught in medical school. However, errors and adverse outcomes are still frequent in clinical practice in spite of increased attention to quality. To improve patient safety, preventing harms associated with the delivery of healthcare is a key component of overall quality of care (Nabhan et al., 2012). Several streams have been emerged to implement safe practices, to achieve a high level of safety in our health care organizations. One of the method is the need for monitoring, assessing, and improving physician performance (Leape & Fromson, 2006).

The Hallas criteria classify ADEs as preventable, probably preventable, probably not preventable or definitely not preventable. Preventable ADEs includes those arising from the prescription of potentially inappropriate medicines and suboptimal monitoring and dose adjustment that could have been entirely avoided. Non-preventable ADEs includes allergic or idiosyncratic reactions (Hallas et al., 1990).

Inappropriate prescribing includes the use of medicines where the risk of ADEs exceeds the expected clinical benefit in patients, especially where safer alternatives exist. Inappropriate prescribing also includes incorrect use of medicines (inappropriate dose or duration), prescription of medicines with clinically significant drug-drug or drug-disease interactions, and importantly,
the under-use of potentially beneficial medications (Hamilton, Gallagher, & O'Mahony, 2009).

Polypharmacy is the main risk factors of ADEs in older people. In practice, polypharmacy can be defined as “using more than a certain number of drugs, irrespective of the appropriateness of their use”. All pharmaceutical agents have the potential for side effects; therefore, it is obvious that taking more than one drug increase the possibility to obtain more side effects (Masoodi, 2008). Another factor is the frailty of older people, means that older people take much longer time to recover than younger people (Vincent, 2010).

Inappropriate prescribing may be identified using lists of medications that are considered potentially inappropriate for older adults such as Beers’ criteria. Beer’s criteria consist of lists of medications to be avoided in elderly patients based on diagnosis, and do not address under-prescribing, drug-drug interactions or drug class duplication (Beers, 1997). In Europe, the STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions) criteria were validated. STOPP criteria are uniquely designed for use alongside the START (Screening Tool to Alert doctors to the Right Treatment) criteria, which highlight under-prescription or omission of clinically indicated, evidence-based medications, thereby addressing more domains of prescribing appropriateness than Beers’ criteria alone (Gallagher & O’Mahony, 2008). Both in Beer’s and START-STOPP criteria, anticholinergic drugs are considered as potentially inappropriate medications and therefore should be avoided in elderly patients.

2.4.3. Models of Adverse Events

Person approach

The person approach focuses on errors from individual perspective. People are viewed as free agents that are responsible for causing error. To reduce error, efforts are targeted as individuals and involve advices “to do better”, retraining, or adding new rules and procedures. Legal perspectives on error
and medical negligence are based on the concepts of personal responsibility, fault, blame and amends. Since this approach focuses on the individual that cause error, it isolates errors from their system context and ignores the circumstances and situations surrounding the errors. As a result, it may impede the pursuit of greater safety (Reason, 2000; Vincent, 2010).

**System approach**

The system approach focuses on fallibility as a part of the human condition and errors are to be expected, even in the best organizations. It concentrates on the conditions and underlying problems in the working environment and tries to build system defenses of barriers and safeguards to reduce errors. When an adverse event occurs, the focus is not on blaming the person who caused the error, but on how and why the defenses system failed (Reason, 2000; Vincent, 2010). High-reliability organizations, for instance aerospace, are the prime examples of the system approach. They have fewer accidents, recognize that human variability is the approach to prevent errors, but they work hard to focus on human variability and are preoccupied with the possibility of failure. They expect to make error and train their workforce to recognize and recover them (Reason, 2000).

**2.4.4. Safety – II Approach**

The publication of the Institute of Medicine (IOM) report To Err is Human in 2000 served as a catalyst for a growing interest in improving the safety of health care. Most people think of safety as the absence of accidents and incidents (or as an acceptable level of risk). Healthcare system consists of highly complex sociotechnical systems and thus differs from other high-risk sectors. Therefore, existing safety management methods should be supplied with new approaches to prevent patient harm (Hudson, 2003; Reason, 2000).

In this perspective, Hollnagel, Wears, and Braithwaite (2015) developed an approach to improve safety management. Safety-II is concentrating on the positive ‘things that go right’ in daily operations. The principle is to anticipate
rather than experience hazards, and adapt to situations rather than respond to unwanted events. Variations in human performance are not only causes of errors. They also provide an ability to adjust the activities. A Safety-II view requires some new practices as following, to look for what goes right, to focus on frequent events, to remain sensitive to the possibility of failure, to be thorough as well as efficient and to consider investing in safety as an investment in productivity (Hollnagel et al., 2015).

The illustration is adapted from World Health Organization's research cycle. It describes a process of identifying error to reduce or avoid unwanted events (fig. 1)

Figure 1. Based on the World Health Organization's research cycle (2015)
3. METHODS

This study used quantitative methods as research method. Quantitative research is particularly suited for:

- Finding answers to a research question that demands a quantitative answer.
- Explaining phenomena and testing of hypotheses.
- Determining how common a phenomenon is.
- Detecting associations between measured variables and make generalizations.

3.1. Research Design

This study was conducted as a longitudinal cohort study in home-dwelling patients with mild dementia in Western Norway. A longitudinal cohort study is a study where a group sharing common characteristics is followed over time to determine the proportion that develops an outcome. These will be classified as one group who are “exposed” and another group “not exposed” to possible risk factors (Cook, Netuveli, & Sheikh, 2003).

3.2. Data Collection

In the Dementia Study of Western Norway (DemVest study), all referrals to five outpatient clinics in geriatric medicine and old age psychiatry with a first time diagnosis of mild dementia (MMSE ≥20), in Rogaland counties (Stavanger and Haugesund) and Hordaland (Bergen) were included. In addition, the three neurology clinics in the region were invited to refer patients with suspected dementia to one of the participating centers. The main inclusion period was from March 2005 to March 2007. After this, only patients with dementia with Lewy bodies (DLB) or Parkinson’s disease dementia (PDD) were included until 2013.
A research clinician performed a structured clinical interview of patients and caregivers regarding demographics, previous diseases and drug history. The comprehensive assessment procedure included a detailed disease history, clinical examination including physical, neurological, psychiatric and neuropsychological examinations, and routine blood tests.

After a comprehensive baseline assessment, patients were followed longitudinally and reassessed annually for 5 years. During the clinical follow-up, the diagnosis was reevaluated and the final diagnosis was made as a consensus between two experienced clinical dementia researchers in geriatric psychiatry. In total there were 266 patients having dementia in inclusion, but 12 patients were excluded because the MMSE score was too low, leaving 254 patients for this study. Everyone lived at home with their spouse or other caregivers at the time of inclusion. Of these, 28 patients died before first follow-up, but there were no dropouts for other reasons.

3.3. Inclusion Criteria

All patients diagnosed with mild dementia for the first time, i.e. having a Mini Mental State Examination (MMSE) score of at least 20 (Folstein, Folstein, & McHugh, 1975), and living at home with their spouse or other caregivers were included.

3.4. Exclusion Criteria

Patients were excluded if they did not have a dementia diagnosis or had acute delirium or confusion, had a terminal illness or recently were diagnosed with a major somatic illness or if they had bipolar disorder or other psychotic disorders.
3.5. Assessments

3.5.1. Dementia Diagnosis

The diagnosis of dementia was made according to the Diagnosis and Statistical Manual for Mental Disorders, 4th edition (DSM-IV), and classification of dementia according to consensus criteria (Emre et al., 2007; McKeith et al., 2005; McKhann et al., 1984). The diagnosis of Alzheimer’s dementia was made according to The National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s disease and Related Disorders Association (McKhann et al., 1984). The diagnosis of dementia with Lewy body was made according to the revised consensus criteria (McKeith et al., 2005), and Parkinson’s disease with dementia according to the recommendation from the Movement Disorder Society Task Force (Emre et al., 2007). The determination of diagnosis of other forms of dementia has been described in details in another study (Aarsland et al., 2008). The diagnostic criteria were independently applied by two of the authors in a previous cohort study. In case of disagreement, the final ascertainment was made based on consensus.

Since DLB and PDD share clinical and pathological features (Tsuboi & Dickson, 2005), they were combined and will from now collectively be referred to as the Lewy body dementia (LBD) group in this study. Vascular dementia, frontotemporal dementia and alcoholic dementia were grouped together and are referred to as other forms of dementia, due to small sample size.

3.5.2. Clinical Assessment

The clinical assessment was performed at each follow-up. Cognition was assessed with the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and Clinical Dementia Rating (CDR) (Berg, 1988). A trained research nurse scored the MMSE and the CDR was scored by a trained research physician. The scoring was made independent of the other cognitive tests, by the same clinician at every occasion to the extent possible.
The MMSE is the most commonly used cognitive screening test in primary level of care. The MMSE consist of several cognitive functions area, such as orientation, registration, recall, attention and calculation, language and complex commands. The results are summarized into a score that ranges from 30 (best) to 0 (worst), spanning the spectrum from normal cognition to severe dementia. A score of 24 or lower is indicative of cognitive impairment (Wyller, 2011).

A study by Perneczky et al. (2006) found that MMSE scores of 29-26, 25-21, 20-11, and 10-0 matched the CDR scores of 0.5, 1, 2 and 3, as questionable dementia, mild dementia, moderate and severe dementia, respectively. Therefore, in this study, the stage of severe dementia is defined as MMSE scores of 10 or lower and CDR score equal to 3.

CDR was used to assess severity of dementia staging by evaluating the degree of impairment in six domains of functioning at baseline and follow-up assessment. The CDR, first published in 1982, rated the patient’s impairment in six domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care). Subsequently, an algorithm is used to integrate the six domain scores into a global score. The CDR global scores are: 0 (no dementia), 0.5 (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). The CDR has become an international standard for the staging of dementia with high validity and reliability (Perneczky et al., 2006).

Cumulative Illness Rating Scale (CIRS) was used to describe the total burden of medical illness, which measures the severity of chronic disease (Linn, Linn, & Gurel, 1968). The total score on the CIRS ranges from 0 to 56; however, a score above 25–30 implies severe pathology in several systems (Hudon, Fortin, & Vanasse, 2005).
3.5.3. Measurement of Anticholinergic Potency and Anticholinergic Load

The anticholinergic activity of drugs used at baseline was estimated using the anticholinergic risk scale developed by Durán, Azermai, and Vander Stichele (2013). This scale is modulated by systematically reviewing existing anticholinergic risk scales. In this study, the scale was classified in three categorical score, 0 (no anticholinergic activity), 1 (low anticholinergic activity) and 3 (high anticholinergic activity) in accordance with Beuscart et al. (2014). For drugs that were not included in Durán’s study or in case of discrepancies between score, anticholinergic activity were specified by authors (JJ and RO) using Martindale, the complete drug reference, which is considered a reputed reference source (Brayfield, 2014), to take the final decision about the anticholinergic activity of the drug.

Anticholinergic drug load was defined as the cumulative effect of taking one or more drugs with anticholinergic activities. The anticholinergic activity score from every agent used by each patient were summed up, and the sum score was defined as the total anticholinergic drug load. Moreover, the total score was categorized into total score 0 (no anticholinergic drug load), \( \leq 2 \) (low anticholinergic drug load) and \( \geq 3 \) (high anticholinergic drug load).

3.6. Statistical Analysis

Statistical analyses of the data were performed using SPSS Statistics version 21.0 from IBM. Independent sample t-test was used to compare means of continuous parametric variables. Mann-Whitney U test was used in cases with two nonparametric continuous variables. The \( \chi^2 \)-test was used to explore the relation between categorical variables.

The Kaplan-Meier survival analysis was used to estimate the median time to severe dementia and the log rank test was performed to compare median time to severe dementia with respect to diagnosis, number of medications, use of anti-dementia, baseline MMSE total score, CIRS total score and CDR global
score at baseline. To analyze time to severe dementia, defined by CDR=3 and MMSE 0-10 (Perneczky et al., 2006) and to explore potential predictors associated with severe dementia, a Cox regression analysis was conducted. The independent factors are age, gender, education, dementia diagnosis, number of drugs used at baseline, use of anti-dementia medication, baseline MMSE total score and CDR global score, comorbidity as measured by CIRS and total anticholinergic load. The dependent factors are use of anticholinergic drugs. The primary outcome variable is the rate of cognitive decline, that is, the MMSE and CDR scores. Subsequently, variables that were significant were included in a multivariable stepwise regression model with backward elimination (likelihood ratio).

The Cox proportional hazards model investigates the relationship of predictors and the time to event through the hazard function. It assumes that the predictors have a multiplicative effect on the hazard and that this effect is constant over time. The hazard ratios (HR), defined as the ratio of the predicted hazard function lower than two different values of a predictor variable. A hazard ratio greater than 1 means the event is more likely to occur, and a ratio less than one means an event is less likely to occur. A hazard ratio of 1 means the predictor has no effect on the hazard of the event. Also, due to the regression framework of the model, one can get hazard ratio estimates that are controlled for other covariates in the model such as age, sex, and race (George, Seals, & Aban, 2014).

Furthermore, log minus log probability plot was performed to check the proportionality of the hazards model and the curves was approximately parallel and did not intersect after time apart. Two-sided p-values lower than 0.05 was considered as statistically significant. Results are presented as means, stated with their standard deviation (±SD), median with interquartile range (IQR) or 95% confidence interval (CI).
3.5 Ethical Considerations

The study was approved by the Regional Committee for Medical and Health Research Ethics (REK) in Western Norway (Ref.nr: 2016/29/REK vest). Written informed consent was obtained from all subjects after the study procedures had been explained to them and caregivers.
4. RESULTS

4.1. Baseline Characteristics

A total 254 patients were included at baseline with an average age of 75.7 years (SD 7.6). The majority of the patients were diagnosed with Alzheimer disease (48.8%). The demographic and clinical baseline characteristics are summarized in table 1.

<table>
<thead>
<tr>
<th>Table 1. Demographic and characteristic of the study population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total sample</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Number of participant, n(%)</td>
</tr>
<tr>
<td>Age at baseline, years (means ± SD)</td>
</tr>
<tr>
<td>Female (n,%)</td>
</tr>
<tr>
<td>Years of education</td>
</tr>
<tr>
<td>Diagnosis (n,%)</td>
</tr>
<tr>
<td>Alzheimer dementia</td>
</tr>
<tr>
<td>Lewy Body Dementia</td>
</tr>
<tr>
<td>Other forms of dementia</td>
</tr>
<tr>
<td>MMSE score</td>
</tr>
<tr>
<td>CDR score ≤ 1 (n,%)</td>
</tr>
<tr>
<td>CIRS score</td>
</tr>
<tr>
<td>Number of drugs</td>
</tr>
<tr>
<td>Anti dementia medication (n,%)</td>
</tr>
</tbody>
</table>

Values are median and interquartile range (IQR), except where otherwise indicated. The groups using and not using anticholinergic drugs were compared using the independent samples t-test (age), Mann-Whitney test (education, MMSE, CIRS and number of drugs) and chi-square test (sex, CDR, diagnose and use of anti dementia medication).
MMSE: Mini-Mental State Examination, CDR: Clinical Dementia Rating, CIRS: Cumulative Illness Rating Scale
a) \( p = 0.149 \), independent t-test  
b) \( p = 0.781 \), Chi-square test  
c) missing data for 6 cases, \( p = 0.995 \), Mann-Whitney test  
d) \( p = 0.057 \), Chi-square test  
e) \( p = 0.016 \), Mann-Whitney test  
f) missing data for 17 cases, \( p = 0.650 \), Chi-square test  
g) missing data for 19 cases, \( p < 0.005 \), Mann-Whitney test  
h) \( p < 0.005 \), Mann-Whitney test  
i) \( p = 0.121 \), Chi-square test

4.2. Use of anticholinergic drugs

Drugs with anticholinergic activity were used by 145 patients (57.1%). Of these, 59 (51.8%) were taking at least one anticholinergic medication. Moreover, 114 patients (44.9%) were taking anti dementia medications at baseline. Patients who used drugs with anticholinergic activity also had more comorbidity and a significantly higher number of medications compared to nonusers (\( p < 0.005 \)) (table 1).

Drugs with low anticholinergic activity were used by 138 patients (54.3%), whereby 53 patients (38.4%) of these took two or more anticholinergic drugs. Drugs with high anticholinergic activity were used by 30 participants (11.8%) and two of them used two drugs with high anticholinergic activity. A total of 44 patients (30.3%) had high cumulative anticholinergic load (total score of anticholinergic activities \( \geq 3 \)).

The most common drugs with low anticholinergic activity taken overall among the elderly dementia patients were escitalopram (19%), followed by oxazepam (14%). Among drugs with high anticholinergic activity, tolterodine (23%) and ipratropium (3%) were most frequently used.

The mean of total anticholinergic drug load was 1.23 ± 1.60 (range 0-8). Our findings revealed that higher total scores of anticholinergic load were due to the summative effect of multiple low potency anticholinergic medications (up to six medications), rather than a single drug with high anticholinergic properties.
Follow-up data on cognition were available for 226 patients (96 males and 130 females) of whom 115 (50.9%) had AD, 66 (29.2%) had LBD and 45 (19.9%) had other form of dementia diagnosis. Of these, 129 patients (57.1%) and 107 (47.3%) were taking anticholinergic medication and anti-dementia medicines at baseline, respectively. Among these patients, 188 patients (83%) had low anticholinergic load and 38 (17%) with high anticholinergic load.

During the observational period 172 patients died, but there were no dropouts for other reasons. The time to severe dementia was significantly higher in AD (3.9 years) compare to LBD (3.2 years) and other forms of dementia (2.5 years). However, there was no significant difference in age, sex, education and use of anti dementia medicines (p > 0.05 for all comparisons).

**4.3. Predictors of cognitive decline**

The median time to severe dementia, defined as MMSE ≤ 10 and CDR = 3, was 1894 days and 1915 days in patients that use anticholinergic drugs, and 1863 days and 1933 days in nonusers, (p=0.744 and p=0.652), respectively. Multivariable Cox regression analysis was run to determine the effect of baseline covariates on time to worsening of cognitive decline and severe dementia.

Having a diagnosis of LBD or other forms of dementia and having a high CDR global score at baseline was associated with shorter time to MMSE score decline over time (table 2). These factors remained statistically significant predictors for the progression of MMSE decline even after adjusting for relevant confounders. Conversely, having a high MMSE total score or a high CIRS total score at baseline decreased the risk for MMSE decline significantly (adjusted HR 0.9 and 0.83, p<0.005, respectively, table 2).

The study revealed no significant interactions with anticholinergic drugs use (p=0.744). Time to severe dementia (MMSE ≤10) was slightly more rapid for
those who used anticholinergic drugs in the early years, but remained almost the same after five years (figure 2).

Table 2. Factor associated with the rate of decline on MMSE

<table>
<thead>
<tr>
<th>Factor</th>
<th>Unadjusted HRs (95% CI)</th>
<th>p Value</th>
<th>Adjusted HRs (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.98 (0.95 – 1.01)</td>
<td>0.333</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex, female</td>
<td>0.89 (0.57 – 1.42)</td>
<td>0.636</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education, years</td>
<td>1.02 (0.95 – 1.11)</td>
<td>0.555</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LBD</td>
<td>1.74 (1.03 – 2.95)</td>
<td>0.005</td>
<td>1.97 (1.11 – 3.49)</td>
<td>0.025</td>
</tr>
<tr>
<td>Other dementia</td>
<td>0.45 (0.19 – 1.05)</td>
<td>0.005</td>
<td>0.64 (0.26 – 1.55)</td>
<td>0.025</td>
</tr>
<tr>
<td>No. of drugs</td>
<td>0.87 (0.79 – 0.97)</td>
<td>0.007</td>
<td>0.93 (0.81 – 1.06)</td>
<td>0.267</td>
</tr>
<tr>
<td>CDR-GS ≤ 1 at baseline</td>
<td>1.43 (0.89 – 2.27)</td>
<td>0.132</td>
<td>1.68 (1.03 – 2.74)</td>
<td>0.036</td>
</tr>
<tr>
<td>MMSE total scores</td>
<td>0.90 (0.82 – 0.99)</td>
<td>0.034</td>
<td>0.90 (0.82 – 0.99)</td>
<td>0.038</td>
</tr>
<tr>
<td>CIRS total scores</td>
<td>0.87 (0.78 – 0.96)</td>
<td>0.004</td>
<td>0.83 (0.75 – 0.93)</td>
<td>0.001</td>
</tr>
<tr>
<td>Antidementia drugs use</td>
<td>1.70 (1.07 – 2.72)</td>
<td>0.024</td>
<td>1.33 (0.8 – 2.20)</td>
<td>0.272</td>
</tr>
<tr>
<td>Anticholinergic medicines</td>
<td>0.93 (0.59 – 1.46)</td>
<td>0.744</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total ACH load</td>
<td>0.94 (0.8 – 1.12)</td>
<td>0.490</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cox regression, time until MMSE 0-10, HRs presented with 95% CI.
Abbreviations: HR: Hazard Ratio, CI: Confidence Interval, LBD: Lewy-body dementia, CDR-GS: Clinical Dementia Rating Global Scores, MMSE: Mini-Mental State Examination, CIRS: Cumulative Illness Rating Scale, ACH: anticholinergic drug

Factor associated with time to severe dementia (CDR-GS = 3) is shown in table 3. Having LBD and other forms of dementia (adjusted HR 2.14 and 0.5, p=0.003) and higher CDR-GS at baseline (adjusted HR 1.83, p=0.019) remained significant predictors of a time to reach severe dementia. Higher baseline MMSE and CIRS score was considered as protective factors to severe dementia (p<0.005). We also conducted multivariable Cox regression analysis including anti dementia drug use in the model, which predicted shorter time to MMSE decline and severe dementia, but it was not statistically significant.
Figure 2. Time to decline on MMSE score with use of anticholinergic drugs and nonusers

Table 3. Factor associated with time to reach severe dementia (CDR = 3)

<table>
<thead>
<tr>
<th></th>
<th>Unadjusted HRs (95% CI)</th>
<th>p Value</th>
<th>Adjusted HRs (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.99 (0.96 – 1.02)</td>
<td>0.591</td>
<td>0.96 (0.89 – 1.05)</td>
<td>0.968</td>
</tr>
<tr>
<td>Sex, female</td>
<td>1.01 (0.63 – 1.64)</td>
<td>0.959</td>
<td>1.04 (0.97 – 1.12)</td>
<td>0.319</td>
</tr>
<tr>
<td>Education, years</td>
<td>1.04 (0.97 – 1.12)</td>
<td>0.319</td>
<td>1.02 (0.87 – 1.06)</td>
<td>0.854</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LBD</td>
<td>2.22 (1.31 – 3.77)</td>
<td>0.001</td>
<td>2.14 (1.21 – 3.78)</td>
<td>0.003</td>
</tr>
<tr>
<td>Other dementia</td>
<td>0.52 (0.22 – 1.23)</td>
<td>0.001</td>
<td>0.5 (0.21 – 1.2)</td>
<td>0.003</td>
</tr>
<tr>
<td>No. of drugs</td>
<td>0.96 (0.87 – 1.06)</td>
<td>0.405</td>
<td>1 (0.89 – 1.14)</td>
<td>0.968</td>
</tr>
<tr>
<td>CDR-GS ≤ 1 at baseline</td>
<td>1.75 (1.08 – 2.83)</td>
<td>0.021</td>
<td>1.83 (1.01 – 3.05)</td>
<td>0.019</td>
</tr>
<tr>
<td>MMSE total scores</td>
<td>0.84 (0.75 – 0.93)</td>
<td>0.001</td>
<td>0.84 (0.75 – 0.94)</td>
<td>0.002</td>
</tr>
<tr>
<td>CIRS total scores</td>
<td>0.96 (0.88 – 1.05)</td>
<td>0.379</td>
<td>0.91 (0.83 – 1)</td>
<td>0.040</td>
</tr>
<tr>
<td>Antidementia drugs use</td>
<td>1.33 (0.83 – 2.13)</td>
<td>0.232</td>
<td>1.45 (0.91 – 2.32)</td>
<td>0.121</td>
</tr>
<tr>
<td>Anticholinergic drugs use</td>
<td>1.11 (0.7 – 1.78)</td>
<td>0.652</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total ACH load</td>
<td>1.02 (0.87 – 1.2)</td>
<td>0.854</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Cox regression, time until CDR = 3. Abbreviations: HR: Hazard Ratio, LBD: Lewy-body dementia, CDR-GS: Clinical Dementia Rating Global Scores, MMSE: Mini-Mental State Examination, CIRS: Cumulative Illness Rating Scale, ACH: anticholinergic drug

Patients that use anticholinergic drugs had a shorter time to reach the severe dementia stage over time compared to nonusers, but they did not differ statistically significant (figure 3).

**Figure 3. Observation time until severe dementia with anticholinergic drugs use and nonuser**

Furthermore, log minus log probability plot was performed to check the proportionality of the hazards model (see figure 4 and figure 5 in attachments).
5. DISCUSSION

5.1. Main finding

The use of drugs with anticholinergic properties was common in these patients with dementia. Our longitudinal study found that 57% of home-dwelling elderly persons with dementia were taking drugs with anticholinergic activities, and nearly 12% were taking one or more anticholinergic medications with high activity. These findings are consistent with the reported prevalence in previous studies (Bhattacharya R., 2011; Mate et al., 2015; Sura et al., 2013).

Almost 40% patients in this current study were taking more than one (up to a value of six) anticholinergic medications with low activity. Our findings revealed that higher total scores of anticholinergic load were due to the summative effect of multiple low activity anticholinergic medications (up to six medications), rather than a single drug with high anticholinergic activities. The results are in line with previous research by Mate et al. (2015). This rate is concerning because previous studies reported that adverse drug events are often the result of cumulative anticholinergic drug load of multiple medications rather than of a single compound (Gerretsen & Pollock, 2013; Pasina et al., 2013; Tune, 2001).

A number of studies have reported that medicines with low anticholinergic activities, including nonprescription medicines, may contribute to older person’s anticholinergic drug load and as consequent cause adverse events, such as negative cognitive effects. However, it was assumed to be reversible and transient (Ancelin et al., 2006; Boustani, 2008). Reducing the number and dose of medicines with anticholinergic potencies may decrease anticholinergic drug load (Bell et al., 2012). Hence, to diminish adverse effects on the dementia patients and those with cognitive impairment, clinicians should consider using alternative medications with no-to-minimal anticholinergic properties.
Participants that use drugs with anticholinergic properties had more often comorbid disease, lower MMSE at baseline and used more drugs than the non-users. Our findings support the recent studies that reported by Luukkanen et al. (2011) and Mate et al. (2015).

Patients with dementia often have additional multiple chronic diseases e.g. cardiovascular disease, requiring use of multiple drugs (Schubert et al., 2006). However, it is important to recognize that many drugs in daily long-term use have anticholinergic properties and that the use of these drugs cannot be fully avoided (Luukkanen et al., 2011).

The most frequently used drug classes with anticholinergic effects in our study were escitalopram (19%) and oxazepam (14%) for low anticholinergic activities. Escitalopram is an antidepressant of selective serotonin reuptake inhibitors class. Depressive symptoms have been reported in up to 40% of patients with Alzheimer disease, which is reflected in the high prevalence of antidepressant use in this population. However, a previous study found that the most frequently medication associated with ADEs is selective serotonin reuptake inhibitors (Gandhi et al., 2003). For that reason, use of antidepressant may be considered as inappropriate due to the increased risk of adverse events (Bell et al., 2012).

Tolterodine (23%) and ipratropium (2.8%) were the most common drugs with significant anticholinergic effects taken in the current study. Tolterodine is used for symptomatic treatment of urinary incontinence. These results are in line with a previous study which found that patients with dementia having urinary incontinence were more likely to use drugs with clinically significant anticholinergic potencies (Sura et al., 2013).

Urinary incontinence is often multifactorial in elderly patients with dementia and may be drug induced. Use of medicines with sedative properties (e.g. benzodiazepines and tricyclic antidepressants) and cholinesterase inhibitors (primarily used to treat the cognitive symptoms of dementia) have also been
associated with urinary incontinence. Anticholinergic medicines (e.g. tolterodine) are often not needed to treat urinary incontinence, especially if potential adverse events are taken into consideration (Bell et al., 2012). Tolterodine have associated with memory deficits and delirium, and therefore non-pharmacologic alternatives are preferred treatments to treat urinary incontinence in people with dementia (Edwards & O’Connor, 2002; Sura et al., 2013).

The study findings raise concern regarding inappropriate prescribing practices in dementia patients. Clinicians should consider the benefit-risk ratio of anticholinergic drugs and base their decision on individual patient characteristics and available evidence-based guidelines in order to avoid adverse events and enhance patient safety. This measure is in accordance with the concept of Safety-II (Hollnagel et al., 2015), which is to anticipate rather than experience hazards, and adapt to situations rather than respond to unwanted events.

Given the potential risk of anticholinergic drug use in elderly, a better understanding of the causes of frequent prescription is needed. Adverse drug-related events are frequent in primary care, and many are preventable or ameliorable. Ameliorable adverse drug events, which were much more common than preventable events, occurred when physicians failed to respond to medication-related symptoms and when patients failed to inform physicians about such symptoms. Therefore, improvements in monitoring for and responding to symptoms appear to be especially important for the prevention of adverse drug events in patients with dementia (Gandhi et al., 2003). This recurrent process of understanding causes and identifying solution on preventing unwanted outcome is in line with World Health Organization’s adapted research cycle that is illustrated in figure 1. Moreover, avoiding drugs that accelerate cognitive decline in dementia patients may improve the quality of life of these patients.
5.2. Cognitive decline

In contrast to previous studies (Cai et al., 2013; Carriere et al., 2009; Ehrt et al., 2010; Gray et al., 2015), our results showed that use of anticholinergic drugs did not affect the prognosis of worsening cognitive decline over time in home-dwelling people with mild dementia. The results did not support our hypotheses, but the findings were somewhat similar to a longitudinal study by Bottiggi et al. (2006). Their study found that anticholinergic use did not lead an accelerated rate of global cognitive status decline.

The difference between our findings and previous results may be due to our focus on drugs with anticholinergic potencies in mild dementia patients. A recent study focused only on high potency anticholinergic drugs based on pharmacologic properties (Gray et al., 2015) and another study was based on anticholinergic drug lists, which is used for routine clinical practice (Carriere et al., 2009). Detailed assessment of the anticholinergic load in these studies included only the well-known anticholinergic effects, but did not include other drugs associated with such effects (Cai et al., 2013; Carriere et al., 2009; Gray et al., 2015). The only study that included other drugs with anticholinergic properties measured the cognitive decline in patients with Parkinson’s disease (Ehrt et al., 2010). In addition, we did not take into account whether patients actually received the anticholinergic medications. Some medications could have been prescribed pro re nata and may never have been used.

In the adjusted model, our results showed that having LBD diagnosis and higher CDR-GS at baseline increased the time and risk to cognitive decline and severe dementia, whereas higher baseline MMSE score and higher baseline CIRS total score were associated with delayed cognitive decline. These findings are consistent with a previous study that patients with DLB have a more rapid cognitive decline than in AD (Rongve et al., 2016).

Possible explanations for these findings are severe parkinsonism, fluctuations in cognitive impairment, visual hallucinations and depression are more
common in LBD compared to AD. These symptoms may be treated with neuroleptic and antidepressant drugs, whereas having LBD increases the sensitivity to drug reactions, especially neuroleptic medication (McKeith, 2002). It is known that neuroleptic medicines and antidepressant have varying degrees of anticholinergic effects, which may explain the deterioration of cognitive decline in these patients. However, we did not find that patients with LBD used more anticholinergic drugs compared to AD. This could be due to lower number of cases with LBD compared to AD.

In the present study, use of anticholinergic drugs was not discontinued before initiating anti-dementia medicines. Use of anti-dementia medicines predicted shorter time to MMSE decline and severe dementia in the unadjusted model, but was not significant after adjustment for various covariates. These effects may be because the anticholinergic action of drugs may reduce or eliminate the cognitive benefits of anti-dementia medicines (Carnahan, Lund, Perry, & Chrischilles, 2004). Given that the aim of anti-dementia medicines is to improve cognition, anticholinergic drugs could be in the absurd situation of receiving pro-cholinergic drugs to counteract the effects of anticholinergic agents (Ancelin et al., 2006). Therefore, it is important that clinicians review the anticholinergic load of their current medicine regiment before initiating anti-dementia medicines, with the aim of minimizing or ceasing medicines with anticholinergic properties.

5.3. Interventions to improve patient safety in practice

Prescribing drugs with anticholinergic properties to dementia patients is generally considered inappropriate due to their adverse effects even though the current study failed to show an association between use of drugs with anticholinergic activities and cognitive decline in people with dementia. Inappropriate prescribing is included in preventable ADEs and preventing ADEs will improve patient safety and at the same time may enhance quality of life of patients.
As discussed previously, age-related changes on drug metabolism and polypharmacy make prescribing for older people are more challenging, and as a result, more vulnerable to ADEs (Masoodi, 2008; Vincent, 2010). In accordance to the principle of Safety-II and adapted research cycle model from WHO (2015), several strategies may be implemented to prevent and reduce ADEs in anticholinergic drugs to improve patient safety. These strategies can generally be categorized as person- or system based interventions, based on model adverse events as described previously. These interventions should be use together to optimally prevent ADEs.

**Person approach**

One of the method to implement safe practice is the need for improving physician performance (Leape & Fromson, 2006). Given that the risk of ADEs increases with number of medication taken, physicians should ideally review the medication list at each patient encounter. Physicians should know a patient’s medical history before beginning a treatment to handle potential problems. Moreover, physicians should consider dose and adverse effects when prescribing anticholinergic medicine in elderly. Education about commonly prescribed anticholinergic drugs and increased monitoring for side effects could benefit physicians and patients (Gandhi et al., 2003).

Furthermore, reducing the number and dose of medicines with anticholinergic properties, particularly patients with dementia, can lead to fewer ADEs. Therefore, physicians should review the anticholinergic drug load of medicines before initiating other medicines. Moreover, physicians should consider that even medicines with minor anticholinergic activities might contribute to unwanted central and peripheral adverse events if used in combination with other agents with anticholinergic effects (Mate et al., 2015). Thus, attempts should be made to reduce inappropriate drug prescription by using available tools, such as Beer’s criteria and START-STOPP criteria.

The risk of an ADE due to drug interactions is substantially higher when more medications are being prescribed. Physicians should consider drug-drug
interactions of anticholinergic drugs, i.e. before initiating cholinesterase inhibitors or memantine. As discussed previously, the addition of an anticholinergic drug such as tolterodine to patients that use cholinesterase inhibitors can be debilitating. Their opposing effect may result in diminish therapeutic effect (Bell et al., 2012).

To prevent ADEs, interactions may be determined using the drug interactions tool i.e. Lexi-Interact Online, etc. (Zhu & Weingart, 2015). Some institutions have also developed websites that provide information about drug interactions and make it possible for physicians to detect potential adverse effects caused by drug interactions. In addition, changing anticholinergic drugs with alternative medications without or minimal anticholinergic properties may reduce ADEs due to use of anticholinergic drugs.

Some anticholinergic drugs, such as cetirizine (Zyrtec), ranitidine (Zantac), loratadine (Clarytin) and loperamide (Imodium), are available as over-the-counter products. Therefore informing older adults about potentially modifiable risk would allow them to choose alternative products and collaborate with health care professionals to minimize overall anticholinergic use. Consequently, there is a strong need to increase awareness among health care professionals and older people about the potential anticholinergic medication-related risk.

**System approach**

Poorly designed systems trigger errors or make them difficult to detect and may cause medication errors and ADEs. A properly designed system focuses on creating efficient barriers in the working environment that will prevent errors in the future (Reason, 2000). It performs reliably because people are flexible and adaptive and human’s performance variability is no longer seen as a threat. In line with the concept of Safety-II, in a good system, clinicians are able to adjust their work to conditions rather than because they work as imagined (Hollnagel et al., 2015).
Advanced systems of computerized medication ordering, such as those that check the dose of the drug, interactions with other drugs, and allergy to the drug, could have prevented 35% of preventable ADEs caused by illegible handwriting, inappropriate doses, drug interactions, and allergies (Gandhi et al., 2003). These systems may improve medication safety by providing standardization of practice, improving the completeness and legibility of prescriptions, alerting clinicians to drug allergies, drug-drug interactions, and cumulative dose-limits, updating clinicians with the most current medication information and providing dosage adjustment calculations based on clinical features such as weight or renal functions (Agrawal, 2009).

To reduce ADEs, use of electronic medical records to administer medications might be useful. Medication orders that are manually transcribed to a paper medication administration record and used by nurses to administer medications are prone to causing errors and ADEs. Using electronic medical records may help to prescribe appropriate medication and manage medication administration schedules and hence adopted by various medical group and hospital practices (Agrawal, 2009; Masoodi, 2008).

Likewise, pharmacist and clinicians should collaborate to improve pharmacotherapy. A study found that the use of an order-entry system for physicians, which sent electronic prescriptions to a pharmacy, decreased the time pharmacist spent recording prescription data and expanded the time they spent counseling patient (Tierney, 2003).

5.4. Strengths and Limitations of the Study

The strengths of current study included the use of the most recent clinical diagnosis of DLB and the specific and standardized clinical assessment program. Furthermore, the annual assessment was done by the same clinicians and continually updated, which increases the accuracy of diagnosis. Additionally, it is a rather homogeneous study sample with mild dementia at inclusion and low dropout rate. As described above, our study has taken into
consideration drugs with anticholinergic activities, whereas previous studies included only well-known anticholinergic effects. The scale was slightly modified by also including drugs that were not included previously, after independent assessment by the authors. A limitation with this method was that dosage and duration of treatment are not taken into account.

There are some limitations in our study. First, we used the anticholinergic drug scale adapted according to the recent study of Durán et al. (2013), which compared seven different scales. There was a big variation in the scales and the grades given to them. The distinction between low and high activity of anticholinergic drugs in the study might be considered as rather crude. However, that was the only way to achieve a consistent score from the various lists (Durán et al., 2013). Second, the use of drugs with anticholinergic properties was recorded only at baseline and possible changes in medications during the follow-up period were not taken into account, which might have influenced the finding. Since an association between cognitive impairment and drugs with anticholinergic properties has been discussed for many years, clinicians may also have reduced or discontinued anticholinergic therapy during the follow-up. Finally, we might have some interval-censored data that may have lead to a potential bias; therefore, another program will optimize data analysis. However, Cox regression is also adequate to evaluate the progression of cognitive decline in this study.

5.5. Future Research

Anticholinergic drugs are linked with many other poor outcomes in older people, including cognitive decline, constipation and an increased risk for falls. Although this current study did not confirm deleterious effects upon cognition, future research is needed to confirm these findings and to understand the underlying mechanisms. Longitudinal studies are required to determine the effects of increased and decreased anticholinergic load on cognitive function and other clinical outcomes for people with dementia. Furthermore, it would have been interested to investigate the true prevalence of adverse drug events
related to use of anticholinergic drugs among home-dwelling patients with dementia and what we can do to reduce their frequency, severity and consequences.
6. CONCLUSION

The study reported the prevalence of use of drugs with anticholinergic properties and its impact on cognitive decline over time in home-dwelling people with mild dementia. The study found that almost 60% home-dwelling patients with mild dementia stage used drugs with anticholinergic properties. Patients that used drugs with anticholinergic activities were likely having Alzheimer disease, lower baseline MMSE score, comorbidity, polypharmacy and taking anti-dementia medications at baseline. In line with previous studies, the major contributors to anticholinergic load were low level of anticholinergic potencies. The most frequently drugs with low anticholinergic properties that use in this population were escitalopram and oxazepam. Tolterodine and ipratropium were the most commonly used drugs with significant anticholinergic properties. The results showed that use of drugs with anticholinergic properties did not associate with cognitive decline among mild dementia patients. Although this study failed to show that use of drugs with anticholinergic properties increase risk to aggravate cognitive impairment in mild dementia patients, yet, prescribing drugs with anticholinergic properties to dementia patients is generally considered inappropriate due to their adverse effects.

Consequently, there is a strong need to improve the prescribing practices in the elderly, and particularly in those with dementia. To prevent ADEs, it is important to monitor, assess and improve physician’s knowledge and performance in order to prevent inappropriate prescribing. These findings also have public health implications for the education of older people about potential safety risks because some anticholinergic are available as over-the-counter products. To prevent harm to patients, safety management should be supplied with new approaches.

This thesis emphasized the importance to consider how overall drug load may contribute adverse events. A reduction in anticholinergic drug load may result in improved short-term memory, confusion, behavior and delirium, together
with an enhanced quality of life and daily functioning of older people (Feinberg, 1993). Several strategies were suggested to improve prescribing practices and to reduce ADEs in anticholinergic drugs use in order to enhance patient safety. Future researches are needed to confirm these findings and to understand the underlying mechanisms.


clinical dementia rating. *American Journal of Geriatric Psychiatry, 14*(2), 139-144. doi: 10.1097/01.JGP.0000192478.82189.a8


FIGURES

Figure 4. Log minus log plot on MMSE decline

Figure 5. Log minus log plot on survival until severe dementia
Figure 6. Time to decline on MMSE score

Figure 7. Time to severe dementia
Part 2

Article
Abstract

**Background:** From previous studies it is known that use of drugs with anticholinergic effects is not favorable, due to their association to adverse drug events such as worsening of cognitive impairment, especially in elderly patients. However, despite the well-recognized potential for cognitive decline, use of anticholinergic agents continues, even among patients with dementia.

**Objectives:** To estimate the prevalence of anticholinergic drug use and its impact on cognitive decline over time in home-dwelling people with mild dementia in Norway.

**Methods:** Referrals to five outpatient clinics in geriatric medicine, old age psychiatry and neurology in Western Norway during 2005-2013 were included. Standardized clinical measurements and diagnostic criteria were employed. Cognitive decline, using Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE), was assessed for up to 5 years. Cox regression analysis was used to analyze the decline on MMSE and CDR.

**Results:** One or more drugs with anticholinergic properties were used by 145 participants (57%). Of these, 30 participants (11.8%) were taking drugs with high anticholinergic potency. In multiple Cox regression analyses, Lewy body dementia (LBD) and a high CDR global score at baseline were associated with the increased progression of cognitive decline and severe dementia. However, there was no significant association between use of drugs with anticholinergic activities or anticholinergic drug load and impairment in cognitive outcome or severe dementia.

**Conclusion:** Use of drugs with anticholinergic drugs did not increase the time or risk of cognitive decline among home-dwelling people with dementia.

**Keywords:** anticholinergic drugs, dementia, home-dwelling, cognitive impairment
Introduction

Anticholinergic medications are frequently prescribed to older people for diverse conditions, such as urinary incontinence, irritable bowel syndrome, and Parkinson’s disease. Other drugs, such as antihistamines, antidepressants and antipsychotics, have significant unintended anticholinergic effects (1, 2). Peripheral adverse effects include dry mouth and increased heart rate. Central side effects include impaired concentration, confusion, memory impairment and falls (3-5).

Age-related changes make the elderly susceptible to adverse drug effects, especially those with chronic conditions, such as dementia (6), due to increase permeability of the blood-brain barrier and changes in pharmacokinetics and pharmacodynamics. Therefore drugs with anticholinergic effects normally not passing the blood-brain barrier may now penetrate it (6, 7).

Dementia causes impaired cholinergic neurotransmission and subsequently a decrease in cognitive function (3, 8, 9). Numerous studies have observed an association between anticholinergic drug load and the risk of developing cognitive impairment, but their results were conflicting (1, 8, 10, 11). These studies did not include patients with mild dementia, and focused only on drugs with well-known anticholinergic effects.

The prevalence of anticholinergic drug use in older people varies enormously (1, 12). Previous studies have reported that 40-60% of patients with dementia use at least one anticholinergic medication and that 10-20% use drugs with well-known anticholinergic effects (9, 13). The prevalence is even higher in nursing home (9, 14).

As anticholinergic drugs are widely used, many patients are subjected to a high anticholinergic load, which may result in cognitive impairment and delirium (1, 3, 15). Anticholinergic toxicity usually occurs due to the cumulative effects of multiple drugs instead of an overdose of a single dose (16).
To our knowledge, no study has evaluated the prevalence of anticholinergic use and its association with worsening cognitive decline over time in home-dwelling people with mild dementia in Norway. Such information is important for the management of patients with dementia, as avoiding drugs that accelerate cognitive decline may improve the quality of life of these patients.

**Methods**

**Subjects**

Referrals to five outpatient clinics in geriatric medicine and old age psychiatry with a first time diagnosis of mild dementia, defined as Mini Mental State Examination (MMSE) ≥ 20 (17) in Western Norway were included. The main inclusion period was from March 2005 to March 2007. After this, only patients with dementia with Lewy bodies (DLB) or Parkinson’s disease dementia (PDD) were included until 2013. After a comprehensive baseline assessment, patients were followed longitudinally and reassessed annually for 5 years. During the clinical follow-up, the diagnosis was reevaluated and the final diagnosis was made as a consensus between two experienced clinical dementia researchers in geriatric psychiatry. In total there were 266 people having dementia in inclusion, but 12 people were excluded because the MMSE score was too low, leaving 254 people for this study. Everyone lived at home with their spouse or other caregivers at the time of inclusion. Patients were excluded if they did not have a dementia diagnosis or had acute delirium or confusion, had a terminal illness, recently were diagnosed with a major somatic illness or if they had bipolar disorder or other psychotic disorders. In Cox regression analysis, 28 patients (9 patients with Alzheimer’s disease, 12 patients with DLB and PDD, and 7 patients with other forms of dementia) were excluded because of death before first follow-up, but there were no dropouts for other reason. Moreover, 29 patients with CDR-GS at baseline > 1 were also excluded in Cox regression analysis.
**Ethical Issues**

The study was approved by the Regional Committee for Medical and Health Research Ethics (REK) in Western Norway. Written informed consent was obtained from all subjects after the study procedures had been explained to them and caregiver.

**Dementia Diagnosis**

The diagnosis of dementia was made according to the Diagnosis and Statistical Manual for Mental Disorders, 4th edition (DSM-IV), and classification of dementia according to consensus criteria (18-20). Details on recruitment strategy and diagnostic procedures have been described elsewhere (21). Since DLB and PDD share clinical and pathological features (22), they were combined and will from now collectively be referred to as Lewy body dementia (LBD) in this study. Vascular dementia, FTD and alcoholic dementia were grouped together and are referred to as other forms of dementia due to the small sample size.

**Clinical Assessment**

The clinical assessment was performed at each follow-up. Cognition was assessed with the Mini-Mental State Examination (MMSE) (17) and Clinical Dementia Rating (CDR) (23) was used to assess severity of dementia staging by evaluating the degree of impairment in six domains of functioning at baseline and follow-up assessment. Subsequently, an algorithm is used to calculate the CDR global score (CDR-GS) by integrating the score from six domains into one overall score of severity (24). The final CDR-GS categories are: no dementia (0), questionable dementia (0.5), mild dementia (1), moderate dementia (2), and severe dementia (3) (25). Cumulative Illness Rating Scale (CIRS) was used to describe the total burden of medical illness, which measures the severity of chronic disease(26). A study by Perneczky et al. (2006) found that MMSE
scores of 29-26, 25-21, 20-11, and 10-0 matched CDR scores of 0.5, 1, 2 and 3, as questionable dementia, mild dementia, moderate and severe dementia, respectively. Therefore, in this study, the stage of severe dementia is defined as MMSE scores ≤ 10 and CDR = 3.

**Measurement of Anticholinergic Drug Load**

The anticholinergic effect of drugs use at baseline was estimated using the anticholinergic risk scale developed by Durán et al. (27). This scale is modulated by systematically reviewing existing anticholinergic risk scales. In our study, we transformed this scale into three categorical score, 0 (no anticholinergic activity), 1 (low anticholinergic activity) and 3 (high anticholinergic activity) in accordance with Beuscart et al. (28). For drugs that were not included in Duran’s study or in case of discrepancies between score, anticholinergic activity were specified by authors (JJ and RO) using a reputed reference source (29) to take the final decision about the anticholinergic activity of the drug.

The total anticholinergic drug load per patient is calculated by summing the anticholinergic activities from every drug used by each patient. Moreover, the total score was categorized into total score 0 (no anticholinergic drug load), ≤ 2 (low anticholinergic drug load) and ≥ 3 (high anticholinergic load).

**Statistical Analysis**

Statistical analyses of the data were performed using SPSS Statistics version 21.0 from IBM. Independent sample t-test was used to compare means of continuous parametric variables. Mann-Whitney U test was used in case of two nonparametric continuous variables. The χ²-test was used to explore the relation between categorical variables. The primary outcome variable is the rate of cognitive decline, that is, the MMSE and CDR scores. The Kaplan-Meier survival analysis was used to estimate the median time to severe dementia and the log rank test was performed to compare time to severe dementia with
respect to diagnosis, number of medications, use of anti-dementia medicines, MMSE total score, CIRS total score and CDR global score at baseline.

To analyze time to severe dementia, defined by CDR=3 and MMSE ≤10 (25) and to explore potential predictors associated with the severity of dementia, Cox regression analysis was conducted. Furthermore, log minus log probability plot was performed to check the proportionality of the hazards model and the curves was approximately parallel and did not intersect after time apart. Two-sided p-values lower than 0.05 were considered as statistically significant. Results are presented as means, stated with their standard deviation (±SD), median with interquartile range (IQR) or 95% confidence interval (CI).

Results

Study sample

A total 254 patients were included at baseline with an average age of 75.7 years (SD 7.6). The majority of the patients were diagnosed with Alzheimer disease (48.8%) while the rest had LBD (30.7%) or other forms of dementia (20.5%). The demographic and clinical baseline characteristics are summarized in table 1.

Use of anticholinergic drugs

Drugs with anticholinergic effects were used by 145 patients (57.1%). Of these, 59 (51.8%) were taking at least one anticholinergic medication. Patients who used drugs with anticholinergic activity also had more comorbidity, higher CDR score and a significantly higher number of medications compared to nonusers (p<0.005, see table 1).

At baseline, 138 patients (54.3%) were taking drugs with low anticholinergic activity, which 53 patients (38.4%) received more than one drug with low anticholinergic activity. Thirty participants (11.8%) were taking drugs with high anticholinergic activity and two of them received two drugs with high
anticholinergic activity. A total of 44 patients (30.3%) had high cumulative anticholinergic load (total score of anticholinergic activity ≥ 3).

The most frequently used drug classes with anticholinergic effects in our study were escitalopram (19%) and oxazepam (14%) for low anticholinergic activities, and tolterodine (23%) and ipratropium (2.8%) for drugs with significant anticholinergic effects.

Follow-up data were available for 226 patients (96 males and 130 females) of whom 115 (50.9%) had AD, 66 (29.2%) had LBD and 45 (19.9%) had other forms of dementia. Of these, 129 patients (57.1%) and 107 (47.3%) were taking anticholinergic medication and anti dementia medicines at baseline, respectively. However, there was no significant difference in age, sex, education and use of anti dementia medicines (p > 0.05 for all comparisons). During the observational period 172 patients died, but there were no dropouts for other reasons. The survival time was significantly higher in AD (3.9 years) compare to LBD (3.2 years) and other forms of dementia (2.5 years).

Predictors of cognitive decline

The median time to severe dementia, defined as MMSE ≤ 10 and CDR = 3, was 1894 days and 1863 days in patients that use anticholinergic drugs and 1915 days and 1933 days in nonusers (p=0.744 and p=0.652), respectively. Multivariable Cox regression analysis was run to determine the effect of baseline covariates on time to worsening of cognitive decline and degree of dementia. Age, sex, education, dementia diagnosis, comorbidity as measured by CIRS, baseline MMSE and CDR global score and total anticholinergic activity were used as covariates. Subsequently, variables that were significant were included in a multivariable stepwise regression model with backward elimination (likelihood ratio). (Table 2 and 3)

Factors associated with time to progression of cognitive decline and severe dementia is shown in table 2 and 3. Factors that remained significant
predictors of faster cognitive decline and severe dementia, measured with MMSE and CDR, were following: having LBD and a high CDR-GS at baseline. Conversely, having a high baseline CIRS total score and MMSE total score decreased the risk for MMSE decline significantly (p<0.05). Use of antideprenza drug predicted shorter time to MMSE decline and severe dementia, but it was not statistically significant (p=0.272 and p=0.121, respectively).

The rate of cognitive decline over time showed the decrease was slightly more rapid in patients that used anticholinergic drugs compared to nonusers in the earlier years, but remained almost the same after 5 years (figure 1 and 2). In addition, there were no significant interactions with anticholinergic drugs use or total anticholinergic drug load (p>0.05).

**Discussion**

**Main findings**

The use of drugs with anticholinergic properties was common in these patients with dementia. The longitudinal study showed that 57% of home-dwelling elderly with dementia were taking drugs with anticholinergic activities, and nearly 12% were taking one or more anticholinergic medications with high activity. These findings are consistent with the reported prevalence in previous studies (9, 13, 15). Almost 40% of the patients were taking more than one (up to a value of six) anticholinergic medications with low activity.

Our findings revealed that higher total scores of anticholinergic load were due to the summative effect of multiple low potency anticholinergic medications (up to six medications), rather than a single drug with high anticholinergic properties. This is in line with previous studies that reported adverse drug events are often the result of cumulative anticholinergic load of multiple medications and metabolites rather than of a single compound (16, 30, 31). Although anticholinergic use is a significant concern in dementia patients, clinicians may be less aware of the cumulative load of multiple low potency
anticholinergic drugs than well-recognized anticholinergic properties when making prescriptions (3, 32). Hence, to diminish adverse effects on the dementia patients and those with cognitive impairment, clinicians should consider using alternative medications with no-to-minimal anticholinergic properties.

Participants that used drugs with anticholinergic properties had more often comorbid diseases, lower MMSE at baseline and used more drugs than the non-users. Our findings supports a recent study that reported polypharmacy (i.e. taking five or more medications) associated with higher anticholinergic load (15). Patients with dementia often have cardiovascular disease, such as coronary heart disease, stroke, diabetes mellitus and hypertension, requiring use of multiple drugs (33). However, it is important to recognize that many drugs in daily long-term use have anticholinergic properties and that the use of these drugs cannot be fully avoided (34). Consequently, there is a need to evaluate and monitor use of anticholinergic drugs as patient safety practice in elderly patients with dementia.

**Cognitive decline**

In contrast to previous studies (1, 8, 10, 11), our findings concluded that no significant difference in the rate of cognitive decline on MMSE and severe dementia in patients use anticholinergic drugs and non-users. The difference between our findings and previous literature results may be due to our focus on drugs with anticholinergic properties in mild dementia patients. A recent longitudinal study focused only on high activity anticholinergic drugs based on pharmacologic properties (1) and a previous cohort study was based on anticholinergic drug lists, which is used for routine clinical practice (8). Detailed assessment of the anticholinergic load in these studies included only the well-known anticholinergic effects, but did not include other drugs associated with such effects (1, 8, 10). The only study that included other drugs with anticholinergic properties measured the cognitive decline in patients with Parkinson’s disease (11). In addition, we did not take into account whether patients actually received the anticholinergic medications (as some could have
been ordered/prescribed on an as needed basis and patients may never have received the medication).

In the adjusted model, our results showed that having LBD diagnosis and higher CDR-GS increased the time and risk to cognitive decline and severe dementia, whereas higher baseline MMSE scores and higher baseline CIRS total score were associated with delayed cognitive decline. These findings are consistent with a previous study that patients with DLB have a more rapid cognitive decline than in AD (35). Possible explanations for these findings are severe parkinsonism, fluctuations in cognitive impairment, visual hallucinations and depression are more common in LBD compared to AD. These symptoms may be treated with neuroleptic and antidepressant drugs, whereas having LBD increased sensitivity to drug reactions, especially neuroleptic medication (36). It is known that neuroleptic medicines and antidepressant have varying degrees of anticholinergic effects, which may explain the deterioration of cognitive decline in these patients. However, we did not find that patients with LBD used more anticholinergic drugs compared to AD. This could be due to lower number of cases with LBD compared to AD.

In the present study, use of anticholinergic drugs was not discontinued before initiating anti-dementia medicines. Use of anti-dementia medicines predicted shorter time to MMSE decline and severe dementia in the unadjusted model, but was no longer significant after adjustment for various covariates. This effects may be because the anticholinergic action of drugs may reduce or eliminate the cognitive benefits of anti-dementia medicines (37).

The strengths of the current study included the use of the most recent clinical diagnosis of DLB and the specific and standardized clinical assessment program. Furthermore, the annual assessment was done by the same clinicians and continually updated, which increases the accuracy of diagnosis. Moreover, we also used CDR as an outcome measure, to apply a more sophisticated statistical approach. CDR measures the full range of functional deficits due to cognition as judged by a trained clinician, and is more accurate and thorough.
measurement. Additionally, it is a rather homogeneous patient group with mild dementia at inclusion and low dropout rate. As described above, our study has taken into consideration drugs with anticholinergic properties, whereas previous studies included only well-known anticholinergic effects. We slightly modified the scale by also including drugs that were not included previously, after independent assessment by two of the authors. A limitation with this method was that dosage and duration of treatment are not taken into account.

There are some limitations in our study. First, we used the adapted anticholinergic drug scale according to the recent study of Durán et al. (27), which compared seven different scales. There was a big variation in the scales and the grades given to them. The distinction between low and high activity of anticholinergic drugs in the study might be considered as rather crude. However, that was the only way to achieve a consistent score from the various lists (27). Second, the use of drugs with anticholinergic properties was recorded only at baseline and possible changes in medications during the follow-up period were not taken into account, which might have influenced the finding. An association between cognitive impairment and drugs with anticholinergic properties has been discussed for many years and clinicians may also have reduced or discontinued anticholinergic therapy during the follow-up. Finally, we might have some interval-censored data that may have lead to a potential bias; therefore, another program would maybe optimize the data analysis. However, Cox regression is also adequate to evaluate the progression of cognitive decline in this study.

In conclusion, the study revealed that almost 60% home-dwelling patients with mild dementia used drugs with anticholinergic activities. In many cases, it is the low-activity anticholinergic drugs that are the major contributors to anticholinergic load. However, we found no association between use of anticholinergic drugs or anticholinergic drug load and the progression of cognitive decline or severity of dementia stage. Future researches are needed to confirm these findings and to understand the underlying mechanisms.
Acknowledgment

The authors wish to thank the DemWest Study Group and Ingvild Dalen of the Research Department at the Stavanger University Hospital for the kind assistance with the statistical analysis.

Conflicts of Interest

None declared.
References

15. Mate K, Kerr K, Pond D, Williams E, Marley J, Disler P, et al. Impact of Multiple Low-Level Anticholinergic Medications on Anticholinergic Load of


# Attachment

## Tables and Figures

### Tabel 1. Demographic and characteristic of the study population

<table>
<thead>
<tr>
<th></th>
<th>Total sample</th>
<th>Using Anticholinergic Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>Number of participant, n(%)</td>
<td>254 (100)</td>
<td>145 (57.1)</td>
</tr>
<tr>
<td>Age at baseline, years (means ± SD)</td>
<td>75.7 ± 7.6</td>
<td>76.3 ± 7.7</td>
</tr>
<tr>
<td>Female (n,%)</td>
<td>147 (57.9)</td>
<td>85 (33.5)</td>
</tr>
<tr>
<td>Years of education c</td>
<td>9 (7-11)</td>
<td>9 (7-11)</td>
</tr>
<tr>
<td>Diagnosis (n,%) d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer dementia</td>
<td>124 (48.8)</td>
<td>64 (25.2)</td>
</tr>
<tr>
<td>Lewy Body Dementia</td>
<td>78 (30.7)</td>
<td>44 (17.3)</td>
</tr>
<tr>
<td>Other forms of dementia</td>
<td>52 (20.5)</td>
<td>37 (14.6)</td>
</tr>
<tr>
<td>MMSE score e</td>
<td>24 (22-26)</td>
<td>23 (22-25)</td>
</tr>
<tr>
<td>CDR score ≤ 1 (n,%) f</td>
<td>220 (92.8)</td>
<td>120 (54.5)</td>
</tr>
<tr>
<td>CIRS score g</td>
<td>6 (4-8)</td>
<td>6 (4-9)</td>
</tr>
<tr>
<td>Number of drugs used b</td>
<td>4 (2-6)</td>
<td>5 (4-7)</td>
</tr>
<tr>
<td>Use of anti-dementia medications (n,%)</td>
<td>114 (44.9)</td>
<td>59 (23.2)</td>
</tr>
</tbody>
</table>

Values are median and interquartile range (IQR), except where otherwise indicated. The groups using and not using anticholinergic drugs were compared using the independent samples t-test (age), Mann-Whitney test (education, MMSE, CIRS and number of drugs) and chi-square test (sex, CDR, diagnose and use of anti dementia medication).

Abbreviations: MMSE: Mini-Mental State Examination, CDR: Clinical Dementia Rating, CIRS: Cumulative Illness Rating Scale

- a) p = 0.149, independent t-test
- b) p = 0.781, Chi-square test
- c) missing data for 6 cases, p = 0.995, Mann-Whitney test
- d) p = 0.057, Chi-square test
- e) p = 0.016, Mann-Whitney test
- f) missing data for 17 cases, p = 0.650, Chi-square test
- g) missing data for 19 cases, p < 0.005, Mann-Whitney test
- h) p < 0.005, Mann-Whitney test
- i) p = 0.121, Chi-square test
Table 2. Factor associated with the rate of decline on MMSE

<table>
<thead>
<tr>
<th></th>
<th>Unadjusted HRs (95% CI)</th>
<th>p Value</th>
<th>Adjusted HRs (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.98 (0.95 – 1.01)</td>
<td>0.333</td>
<td>1.97 (1.11 – 3.49)</td>
<td>0.025</td>
</tr>
<tr>
<td>Sex, female</td>
<td>0.89 (0.57 – 1.42)</td>
<td>0.636</td>
<td>0.64 (0.26 – 1.55)</td>
<td>0.025</td>
</tr>
<tr>
<td>Education, years</td>
<td>1.02 (0.95 – 1.11)</td>
<td>0.555</td>
<td>0.87 (0.79 – 0.97)</td>
<td>0.007</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LBD</td>
<td>1.74 (1.03 – 2.95)</td>
<td>0.005</td>
<td>1.74 (1.03 – 2.95)</td>
<td>0.005</td>
</tr>
<tr>
<td>Other dementia</td>
<td>0.45 (0.19 – 1.05)</td>
<td>0.005</td>
<td>0.64 (0.26 – 1.55)</td>
<td>0.005</td>
</tr>
<tr>
<td>No. of drugs</td>
<td>0.87 (0.79 – 0.97)</td>
<td>0.007</td>
<td>0.93 (0.81 – 1.06)</td>
<td>0.007</td>
</tr>
<tr>
<td>CDR-GS ≤ 1 at baseline</td>
<td>1.43 (0.89 – 2.27)</td>
<td>0.132</td>
<td>1.68 (1.03 – 2.74)</td>
<td>0.036</td>
</tr>
<tr>
<td>MMSE total scores</td>
<td>0.90 (0.82 – 0.99)</td>
<td>0.034</td>
<td>0.9 (0.82 – 0.99)</td>
<td>0.003</td>
</tr>
<tr>
<td>CIRS total scores</td>
<td>0.87 (0.78 – 0.96)</td>
<td>0.004</td>
<td>0.83 (0.75 – 0.93)</td>
<td>0.001</td>
</tr>
<tr>
<td>Antidementia drugs use</td>
<td>1.70 (1.07 – 2.72)</td>
<td>0.024</td>
<td>1.33 (0.8 – 2.20)</td>
<td>0.272</td>
</tr>
<tr>
<td>Anticholinergic drugs use</td>
<td>0.93 (0.59 – 1.46)</td>
<td>0.744</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total ACH load</td>
<td>0.94 (0.8 – 1.12)</td>
<td>0.490</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cox regression, time until MMSE 0-10.
Abbreviations: HR: Hazard Ratio, CI: Confidence Interval LBD: Lewy-body dementia CDR-GS: Clinical Dementia Rating Global Scores, MMSE: Mini-Mental State Examination, CIRS: Cumulative Illness Rating Scale, ACH: anticholinergic drug

Table 3. Factor associated with time to reach severe dementia

<table>
<thead>
<tr>
<th></th>
<th>Unadjusted HRs (95% CI)</th>
<th>p Value</th>
<th>Adjusted HRs (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.99 (0.96 – 1.02)</td>
<td>0.591</td>
<td>2.14 (1.21 – 3.78)</td>
<td>0.003</td>
</tr>
<tr>
<td>Sex, female</td>
<td>1.01 (0.63 – 1.64)</td>
<td>0.959</td>
<td>0.5 (0.21 – 1.2)</td>
<td>0.003</td>
</tr>
<tr>
<td>Education, years</td>
<td>1.04 (0.97 – 1.12)</td>
<td>0.319</td>
<td>1 (0.89 – 1.14)</td>
<td>0.319</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LBD</td>
<td>2.22 (1.31 – 3.77)</td>
<td>0.001</td>
<td>1.83 (1.01 – 3.05)</td>
<td>0.019</td>
</tr>
<tr>
<td>Other dementia</td>
<td>0.52 (0.22 – 1.23)</td>
<td>0.001</td>
<td>0.84 (0.75 – 0.94)</td>
<td>0.002</td>
</tr>
<tr>
<td>No. of drugs</td>
<td>0.96 (0.87 – 1.06)</td>
<td>0.405</td>
<td>0.91 (0.83 – 1)</td>
<td>0.040</td>
</tr>
<tr>
<td>CDR-GS ≤ 1 at baseline</td>
<td>1.75 (1.08 – 2.83)</td>
<td>0.021</td>
<td>1.83 (1.01 – 3.05)</td>
<td>0.019</td>
</tr>
<tr>
<td>MMSE total scores</td>
<td>0.84 (0.75 – 0.93)</td>
<td>0.001</td>
<td>0.84 (0.75 – 0.94)</td>
<td>0.002</td>
</tr>
<tr>
<td>CIRS total scores</td>
<td>0.96 (0.88 – 1.05)</td>
<td>0.379</td>
<td>0.91 (0.83 – 1)</td>
<td>0.040</td>
</tr>
<tr>
<td>Antidementia drugs use</td>
<td>1.33 (0.83 – 2.13)</td>
<td>0.232</td>
<td>1.45 (0.91 – 2.32)</td>
<td>0.121</td>
</tr>
<tr>
<td>Anticholinergic drugs use</td>
<td>1.11 (0.7 – 1.78)</td>
<td>0.652</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total ACH load</td>
<td>1.02 (0.87 – 1.2)</td>
<td>0.854</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cox regression, time until CDR = 3. HR presented with 95% CI.
Figure 1. Time to decline on MMSE score with use of anticholinergic drugs and nonusers
Figure 2. Observation time until severe dementia with anticholinergic drugs use and nonuser

![Survival Function at mean of covariates](image)
**Author Guidelines**

**Instructions to Authors: British Journal of Clinical Pharmacology (BJCP)**

Papers will be considered for publication if they are relevant to any aspect of drug action in humans. Submission of a manuscript to BJCP will be taken to indicate that

- the content of the manuscript is original and that it has not been published or accepted for publication, either in whole or in part, other than as short abstracts, communications or conference proceedings;
- no part of the manuscript is currently under consideration for publication elsewhere;
- all authors have seen and approved the final version of the submitted paper;
- authors have, if necessary, obtained permission to publish from their employers or institutions;
- approvals are held from any persons acknowledged, or cited as having provided personal communication; and permission has been obtained to use any copyrighted material, such as reproducing a figure from another article, in print and electronic forms, and that the source of the material has been acknowledged.

BJCP publishes papers of various kinds including Original Research Articles, Methods in Clinical Pharmacology, Reviews (including Systematic Reviews), Commentaries, Opinion, Education papers and Letters to the Editor.

Original research articles are grouped under headings, including Clinical trials, Drugs in Pregnancy and Lactation, Drug Interactions, Drug Metabolism, Drug Safety, Human Toxicology, Methods in Clinical Pharmacology, New Drug Mechanism, Paediatric Clinical Pharmacology, Pharmacodynamics (PD), Pharmacoeconomics, Pharmacoepidemiology, Pharmacogenetics, Pharmacokinetics (PK), PK-PD relationships, Therapeutics, and Translational Research. Authors are invited to suggest which heading they feel their manuscript would best fit, and may suggest additional headings if they so wish.
Investigations of human subjects will usually be expected to have been conducted in accordance with good clinical practice, which defines investigator responsibilities, including, among others, qualifications, resources, providing medical care to trial participants, communication with the research ethics committee, protocol, informed consent, data integrity and reporting (http://ichgcp.net/4-investigator). Where this is the case we would expect the principal investigator to be an author.

**PREPARING AND SUBMITTING A MANUSCRIPT**

Once you have read these guidelines in full, please go here to submit your manuscript. You will need to submit three documents:

a. manuscript;

b. covering letter that includes specific statements; and

c. a competing interests statement formatted as per our guidelines.

If your paper is accepted, you will subsequently be required to also submit a copyright transfer agreement form signed by the corresponding author. You will be taken to the Wiley Author Licensing Service to complete this, and full guidance is given there. Please see more below.

Papers must be written in clear, concise UK English. Avoid jargon and neologisms.

Regrettably, the Journal is unable to undertake major corrections to language, which is the responsibility of the author. Because there should be no barriers to getting your research published, however, manuscripts are often returned for English language and formatting issues. Thus, a pre-acceptance Editing Service (comprising English language editing, translation services, manuscript formatting and preparation) is available and can provide you, the author, with expert help to ensure your manuscript is ready for submission. Japanese authors can also find a list of local English improvement services at http://www.wiley.co.jp/journals/editcontribute.html. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.
Note that Japanese fonts must not be used in the creation of files (the standard Adobe Acrobat program is not compatible with these fonts).

Manuscript documents should be typed in double spacing and should be page numbered. **Line numbers must also be added to your manuscript before submission.**

A separate title page should be included (see below). The submitting author need not be the same as the corresponding author.

Authors must have contributed directly to the paper submitted, according to ICMJE guidelines on authorship. For a description of the roles and responsibilities of authors and contributors see here.

Authors may find this resource useful.

**AUTHORS' CHECKLIST**

Authors should ensure that they have provided the following information, when appropriate:

1. A cover letter detailing originality of the manuscript and agreement of all authors and also identifying the **Principal Investigator** who undertook any human studies reported.
2. A title page including a title of no more than 150 characters, all author names and affiliations, and the corresponding author contact information. Also including a running head, keywords and word count.
3. A structured summary of no more than 250 words.
4. ‘What is known about this subject’ and ‘What this study adds’ statements (up to three bullet point sentences for each).
5. 95% confidence intervals (CI) on differences between major end points.
6. Some numerical data in the summary, including 95% CIs, when appropriate.
7. Details of precision, accuracy, sensitivity, and specificity for drug/metabolite assays.
8. A statement (in Methods) of ethics committee approval and subject consent including the name of the ethics committee and the approval number or identification code.
9. A statement declaring any competing interests, or declaring that there are no competing interests.

10. Acknowledgement of financial and other support.

11. Preprints of relevant unpublished papers.

Figures and tables must be submitted as separate files, and guidance on preparing artwork can be found here. The following formats are accepted: gif, jpg, bmp, tif, pic (figures) and as Word and Excel files (tables). PDF and Powerpoint files are not accepted.

The main text file must contain the title page, summary, text, references, and figure legends.

Manuscripts in rich text format should not contain word processor styles (for example bold, italics, justification).

For more information about the online submission system, please see here or email the Editorial Assistant.

Covering letter

Please include in your covering letter the following:

*Statements regarding the originality of the work and agreement of all authors to its publication*

Papers will not be approved for review unless accompanied by a statement, in the covering letter, that they have not been, and will not be published, in whole, or in part, in any other journal, and that all the authors have agreed to the contents of the manuscript in its submitted form. If authors have a problem in contacting a co-author for approval, the reason for this should be explained in the letter and may subsequently be discussed via email with the relevant Senior Editor.

If there is any overlap between a submitted manuscript of an original paper and a paper that is being submitted elsewhere, the submitting author should draw this to the attention of the Editors in the submission covering letter and enclose a copy of the relevant submitted paper(s).

If there is any overlap with a paper that has already been published elsewhere (including online publication), including use of the same subjects or repetition
of any data, that paper must be referred to and cited in full. If your manuscript refers to unpublished data (see section below “References to data on file”), you should obtain (and provide the Editorial Office with a copy) written permission to mention a responsible individual (e.g. “Prof X...contact address a.x@kcl.ac.uk) or should identify a department in a company that can be contacted, with a contact address.

Principal Investigator
For ALL papers describing investigations of human subjects (e.g. Research Papers) please indicate which of the authors was the Principal Investigator. (If the Principal Investigator is not an author of the paper, please explain why not.) BJCP has a policy of not accepting papers of which a person with final medical responsibility is not an author: please see the recent Editor’s View.

Reviewers
Authors can, if they choose, facilitate the review process by providing, as part of the electronic submission process via ScholarOne, the names, institutions and email addresses of up to two suggested reviewers, on the understanding that the Editors are not bound by any such nomination, and that the Editors will check the credentials of these nominated individuals carefully to ensure optimum ethical standards. Opposed reviewers may also be supplied.

Conflicts of interest
All authors must declare any potential conflicts of interest. The corresponding author of an article acts as guarantor and must ensure that this is criterion is fulfilled and a full conflicts of interest statement is supplied to the Publisher. Papers will not be rejected because there is a competing interest: the aim of funding and conflicts of interest statements is not to eradicate conflicts of interest (they are common); it is so that BJCP articles are fully transparent and ethical. A conflict of interest exists when a primary interest (such as the validity of research) might be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors of a BJCP article when they have
a financial interest that may influence their interpretation of their results or those of others. Financial interests are the easiest to define and they have the greatest potential to influence the objectivity, integrity or perceived value of a publication. They may include any or all, but are not limited to, the following:

- **Personal financial interests**: Stocks or shares in companies that may gain or lose financially through publication; consultant or speaker fees; other forms of remuneration from organisations that may gain or lose financially; patents or patent applications whose value may be affected by publication.
- **Employment**: Recent, present or anticipated employment of you or a family member by any organization that may gain or lose financially through publication of the paper.
- **Gifted drugs, materials or devices not commercially available**
- **Patent rights**
- **Consultancy work (past or present).**

Examples of appropriate conflicts of interest statements would be:

- This work was supported by the NIH (grant to AB and CD).
- This work was supported by a grant from Big Pharma Inc. (to AB) and equipment was donated by Small Pharma Inc. EF received a graduate studentship award from the University of xxxxx.
- AB declared no other relationships or activities that could appear to have influenced the submitted work.
- This work was supported by a grant from the National Institutes of Health, USA (DKxxxx to AB).
- This work was supported by the NIH (grant to AB and CD).
- This work was supported by a grant from Big Pharma Inc. (to AB) and equipment was donated by Small Pharma Inc. EF received a graduate studentship award from the University of xxxxx.

For papers where no conflicts of interest or funding are declared, a default statement is added to that paper.

**The peer and publication process**  *BJCP* operates a single-blind peer-review process using a body of expert peer reviewers. Correspondence related to
published research in BJCP is not usually subject to peer review, but is shared with the authors of the original paper prior to any publication, with a right to reply. All substantive papers — i.e. original research and reviews (commissioned and non-commissioned), including those published under our open access programme OnlineOpen — undergo the same rigorous and consistent peer review process.

Once submitted, a manuscript will first be checked by the Editorial Office to ensure all elements have been submitted. If any required documentation is not present, the Editorial Office will return the manuscript to the authors and request any missing information or material.

Once a paper is accepted, it is published within a few days on the journal website in the format of the final accepted version, i.e. as a PDF of the Word version. This final accepted version, known as an ‘Accepted Article’ is fully citable (and has a perpetual Digital Object Identifier [DOI]). Accepted articles are replaced by Early View (see below) and then the final version of record once published in an issue.

Please note submissions are checked using the iThenticate® anti-plagiarism software. Please see here for a quick guide on plagiarism, and here for a full guide.

BJCP publishes Early View articles, which are complete full-text articles published online in advance of their publication in an issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They have the same a DOI as their Accepted Article counterpart, which allows the article to be cited and tracked before it is allocated to an issue. After issue publication, the DOI remains constant and valid and can continue to be used to cite and access the article.

**ORCID**  We strongly encourage all authors to register with ORCID, which provides a persistent digital identifier for individual researchers that, through
integration in key research workflows such as manuscript and grant submission, supports automated links between a researcher and his/her professional activities, ensuring that his/her work is recognised. On submission, you will be given an opportunity to link your ORCID number with your Scholar One account.

**Publishing your paper open access**

OnlineOpen, Wiley's open access programme, is available to BJCP authors who wish to make their article available (immediately) to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. Please see here a helpful guide to compliance. See here for open access policies by funder, and please see below more on copyright.

Prior to acceptance there is no requirement to inform the Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the Journal's standard peer-review process and will be accepted or rejected based on their own merit.

Any authors wishing to send their paper Online Open will be required to complete the payment form.

**Copyright – using the Wiley Author Licensing Service**

The author identified as the formal corresponding author for an accepted paper will, on acceptance of their article, receive an email prompting them to login into Author Services, where, via the **Wiley Author Licensing Service (WALS)**, he/she will be able to complete the relevant copyright or licence agreement on behalf of all authors on the paper.

*For authors signing the copyright transfer agreement*

If the corresponding author does not select the OnlineOpen option in WALS,
he/she will be presented with the copyright transfer agreement (CTA) to sign. (See here for further details.)

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons Licences

- Creative Commons Licence Open Access Agreements (OAA)
- Creative Commons Attribution Non-Commercial Licence OAA
- Creative Commons Attribution Non-Commercial-NoDerivs Licence OAA

If a corresponding author selects the OnlineOpen option and his/her research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) he/she will be given the opportunity to publish the article under a CC-BY licence supporting compliance with Wellcome Trust and Research Councils UK requirements. For more information on funder policies, please see here and here. For a useful guide to ensuring compliance, see here.

Using copyrighted material  It is the author’s sole responsibility to obtain permission to use copyrighted material, including print and electronic forms, in a paper, in advance of submission and to acknowledge fully the source of the material.

Original Research Articles

Papers should be concise and consideration should be given to using supporting information (see http://authorservices.wiley.com/bauthor/suppmat.asp for more information about our Supporting Information service). Most original research articles published in BJCP are between 3000 and 4000 words (for Introduction, Methods, Results and Discussion only). Please refer to a recent issue for examples of length that we regard as appropriate, which varies with the complexity and importance of the study. If you believe your original research paper is going to significantly exceed 4000 words, we require justification for this with your submission letter.

When writing your paper, original research papers should generally be divided into the following sections: Title Page (including PI Statement), Structured
Summary, Introduction, Methods, Results, Discussion, Acknowledgements, References, tables and legends to figures (Please remember that figures must be submitted as separate files). In addition authors should provide material for 2 sections, placing this after the Structured Summary:

Section 1: What is already known about this subject: In up to three short bullet point sentences (not more than 50 words in total) summarise the state of scientific knowledge on this subject before you did your study and say why this study needed to be done.

Section 2: What this study adds: In up to three short bullet point sentences (not more than 50 words in total) give a simple answer to the questions “What do we now know as a result of this study that we did not know before?” and “What take-home-message do you want to impart to the readers?”

These two statements should be succinct, accurate and specific.

All Research Papers require a list of author contributions.

Papers should be concise and consideration should be given to using online publication of supplementary tables or other material (see http://authorservices.wiley.com/bauthor/suppmat.asp for more information about our Supporting Information service).

Review articles

Review articles on a wide range of topics appear regularly in the Journal. Articles may be unsolicited, or may be commissioned by the Reviews Editor. Either kind may be single papers or, by prior agreement with the Editor, part of a themed series. Contributors are welcome to submit single review articles directly (systematic reviews are especially welcome). Most reviews should be between 2500 and 3000 words, should be fully referenced, and if judged potentially suitable will undergo peer review. Each review should include a summary but not the boxes (“what is known”/ “what this adds”) that are required only for original research articles. They will be subject to the other requirements of an original research paper.

From time to time the Journal will publish themed issues, including review articles and related original research papers. Authors who want to suggest a
theme for a special issue should contact the Editor-in-Chief.

**Systematic reviews**
The Journal welcomes systematic reviews. The manuscript should provide a concise account of the methods used, and concentrate on highlighting key aspects of interest and relevance to clinical pharmacologists, under the following headings: Structured Summary, Introduction, Methods, Results, Discussion, and Conclusion.

- **Introduction** This should mention the background (e.g. relevant clinical and pharmacological issues) and describe the scope and aim of the review. What was the reason for the review? The strengths and weaknesses of the existing literature should be briefly described, earlier reviews identified and the need for the present paper explained.

- **Methods** Study selection (search strategy, type of intervention/exposure, types of studies included, types of outcomes, types of participants); data extraction and synthesis (statistical techniques and use of a quality assessment tool, if any).

- **Results** The key characteristics of the included studies and the main outcome measures; discuss variation within and between studies.

- **Discussion** Compare the findings to existing knowledge; outline the limitations of the review.

- **Conclusion** Summarize the key findings and the implications for clinical pharmacology and/or practical drug therapy.

**Letter to the Editor**
Comments on previously published papers, items of topical interest, and brief original communications will be considered under this heading. The length, including references, should not exceed 800 words, plus one figure or table. The letter should NOT be divided into sections.

**Case reports** (must be submitted as Letter to the Editor)
The Journal generally does not publish case reports as full papers but will do so as letters to the Editor. As for other letters the length, including references,
should not exceed 800 words, plus one figure or table. Such case reports (for example adverse drug reactions or interactions) should include some novel aspect of drug action in man (for example a new adverse reaction or one that gives insight into a mechanism or method of management). Such reports may include single cases or short case series. Notes and guidelines on the format for publishing such reports, including a structured summary, will be found at http://www.bmj.com/content/suppl/2003/06/19/326.7403.1346.DC1.

TERMINOLOGY Stereoisomers

When a drug can exist as stereoisomers or diastereomers (for example geometrical isomers), the form of compound studied must be designated as follows in the methods section.

In the case of racemates the prefix rac- should precede the drug name (for example rac-propranolol).

When possible the absolute configuration of enantiomers should be indicated (for example (S)-warfarin).

Similarly, geometrical isomerism should be indicated by the prefixes Z/E or cis/trans. When appropriate, the interpretation of data obtained using mixtures of isomers should take account of stereochemical aspects.

Drug names

Prescribed drugs should be designated by an International Non-proprietary Name (recommended, rINN, or proposed, pINN). If such a name is not available, a drug should be designated by its British Approved Name (BAN; for example hyoscyamine) or its chemical name (for example glyceryl trinitrate).

When a mixture of drugs has a combination BAN (for example co-trimoxazole, co-fluampicil), that should be used.

For brevity, a company’s code name may be used, but in that case the full chemical name or a figure showing the structure of the drug should be given in the introduction or a reference provided that gives this information.

Some mediators with well established common names (e.g. prostacyclin) are also prescribed as licensed preparations with an rINN (e.g. epoprostenol).
such cases the rINN should be used in the context of therapeutic use. Sometimes English and American usage varies, as with adrenaline / epinephrine and noradrenaline / norepinephrine. “Adrenaline / noradrenaline” relate clearly to terms such as “noradrenergic”, “adrenergic” and “adrenal gland” but we will accept the term preferred by authors.

Units
SI units (mass or molar units) should be used. If other units are used, a conversion factor should be included in the Methods section.

Symbols
A set of standard symbols in pharmacokinetics and pharmacodynamics can be found here.

STRUCTURE
Title page
The title page should include
• the title giving an informative and accurate indication of the content of the paper. It should be no longer than 150 characters, including spaces;
• the names, positions, and addresses of the authors;
• the name and e-mail address of the submitting author and the corresponding author, if different;
• a running head of no more than 75 characters, including spaces;
• keywords (these are used to identify potential referees and as indexing terms);
• the word count, excluding the title page, summary, references, tables, and figures;
• the numbers of tables and figures.
In order to ensure correct citation of your article on PubMed, should your article be accepted for publication, please include spaces in-between author's initials on the title page of your manuscript, e.g. A E Smith. If author's initials do not appear on the title page of your manuscript according to these guidelines they may appear incorrectly on PubMed until your article has been typeset and published in an issue.
Summary
The text must be preceded by a structured summary, including the following headings:

• Aim(s)
• Methods
• Results (some numerical data, including confidence intervals on differences, when appropriate, must be included)
• Conclusions

The summary should be a maximum of 250 words; abstracting services truncate summaries that are longer. It should be couched in terms that will be understood by most readers of the Journal.

Analytical methods
Authors should include details of the precision, accuracy, sensitivity, and specificity of an analytical method used to measure drugs, metabolites or biomarkers or refer to other publications in which the information is given.

• Precision is a measure of random error, usually expressed as the coefficient of variation.
• Accuracy is a measure of systematic error, also called bias; it can be expressed as the percentage difference between the result for a test sample and the reference value for that compound.
• Sensitivity or lower limit of quantification.
• Specificity is the extent to which the method does not detect compounds other than those intended.

Statistical methods
In the Methods section statistical methods should be described clearly, with references when appropriate. Editors and referees will be particularly concerned that any study described had sufficient statistical power for its purpose; when appropriate, the power of the study and its calculation should be described in the Methods section.
In the **Results** section 95% confidence intervals of differences should be cited where relevant for important endpoints. This is particularly important when equivalence is being claimed (i.e. for non-significant comparisons). The Editors may utilize specialist statistical referees for manuscript review where necessary.

**Tables**

Tables should generally not have more than 85 characters to a line (counting spaces between columns as 4 characters) and certainly not more than 110 characters to a line, unless absolutely unavoidable. Each table should be typed on a separate page and be in an editable format (doc or xls).

**Figures and use of colour**

Please provide high quality figures suitable for the journal’s production processes. Use of colour (free to authors) is encouraged when it improves the clarity of the message conveyed.

To enhance the presentation of their articles, authors are encouraged to use colours in complementary pairs (example): a primary pair that is close to the colour of the journal and existing tables (example); a secondary pair for use when there are multiple figures side by side, or purely for variety within a paper (example); and a third pair to particularly highlight a figure, possibly in the conclusion/results part of a paper (example). With certain figures when it is helpful to strongly differentiate between sets of results, the first colour of each pair should initially be used (example), with the corresponding extra colours introduced as necessary. As blocks, the suggested colours all work together and should be clear to those readers who are colour-blind (example). Although white backgrounds are generally advisable, if necessary a suggested background colour that works both with the overall look of the journal, and the proposed colour palette is illustrated (example).

Digital files should be prepared in accordance with the instructions that will be found at [http://authorservices.wiley.com/bauthor/illustration.asp](http://authorservices.wiley.com/bauthor/illustration.asp). The eps format (illustrations, graphs, annotated artwork; minimum resolution 800 dpi) and tif format (micrographs, photographs; minimum resolutions 300 dpi) are
recommended, although in some cases other formats can be used.

References

- References should be cited using the Vancouver style (see examples below; for detailed instructions see http://www.icmje.org).
- References in the manuscript text should appear as numbers in square brackets.
- The reference list should show the references in numerical and not alphabetical order, and should include the names of all the authors, the full title of the article, the title of the publication (abbreviated as in Medline or PubMed), the year, the volume number, and the first and last page numbers.
- References to books should include the names of the editors, the edition number, when appropriate, and the place of origin and the name of the publisher.
- The accuracy of the references is the responsibility of the author. Referencing should be thorough but not excessive. Older literature that has been well reviewed can be referred to indirectly by citing the review(s).

Examples:


Accepted articles and Early view

References to papers published as Accepted Articles should be cited thus: Ferro A. Paediatric prescribing: why children are not small adults. Br J Clin

**Archived data**  References to archived data supporting the publication should be cited thus: Brown, LJ; Year. *Dataset title*; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI).

**References to data on file**

Any assertions within a submitted manuscript that are backed up by reference to unpublished data should be clearly noted as such in the body of the manuscript and should give a clear direction to the reader as to how they might request this data: e.g. ‘ACME34178 is not metabolised by CYP3A4 (unpublished data on file, ACME Drug Co. Ltd., Didcot, UK)’, ‘Drug Z is known to partition extensively into erythrocytes (personal communication from Prof. X, University of Y)’

If making such a reference to unpublished data the author should obtain (and provide the Editorial Office with a copy) written permission to mention an individual (Prof X) or should identify a department in a company that can be contacted with an address (Department of Drug Metabolism, ACME Drug Co, drugmet@acme.com) and the permission should come from the head of that department or their designate.

**Acknowledgements**

All support, financial or otherwise, for any work described should be acknowledged, with the exception of support from employing institutions identifiable from the title page. Authors are reminded that if they want to acknowledge the assistance of an individual, it is courteous to ask the individual’s permission to do so.

**Supporting Information**

Supporting Information can be a useful way for an author to include important but ancillary information with the online version of an article. Examples of Supporting Information include additional tables, data sets, figures, movie files, audio clips, 3D structures, and other related nonessential multimedia files.
Supporting Information should be cited within the article text, and a descriptive legend should be included. It is published as supplied by the author, and a proof is not made available prior to publication; for these reasons, authors should provide any Supporting Information in the desired final format. For further information on recommended file types and requirements for submission, please visit: http://authorservices.wiley.com/bauthor/suppinfo.asp

Proofs
Proofs will be sent to the corresponding author and should be returned within 3 days of receipt to the Production Editor. The corresponding author will receive an e-mail alert containing a link to a secure web site. A working e-mail address must therefore be provided for the corresponding author. In the absence of the corresponding author, please arrange for a colleague to access the e-mail to retrieve the proofs.

Acrobat Reader will be required in order to read the proof file and can be downloaded (free of charge) from the following website: http://www.adobe.com/products/acrobat/readstep2.html. This will enable the file to be opened, read on screen, and printed out in order that corrections can be made.

Further instructions will be sent with the proof. In your absence, please arrange for a colleague to access your e-mail to retrieve the proofs.

Corrections should be kept to a minimum. Extensive changes may be charged to the author.

Once proofs have been corrected the paper will be published online in the next available issue. The online version is definitive and there will be no further opportunity for correction. The date of publication of the article is the date of its first appearance online as an Accepted Article.

Author Services
Author Services enables authors to track their article once it has been accepted through the production process to publication online and in print. Submitting authors can check the status of their articles online and choose to receive
automated e-mails at key stages of production, so that they don’t need to contact the production editor to check progress. Visit http://authorservices.wiley.com/bauthor for more details on online production tracking and for a wealth of resources, including FAQs, tips on article preparation, submission, and more.

**Offprints**

Free access to the final PDF offprint of your article will be available *via* author services only. Please therefore sign up for Author Services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers. Although the journal is now published online only, paper offprints can be ordered at prices quoted on the order form that accompanies the proofs, provided that the form is returned with the proofs. These are normally dispatched within 3 weeks of publication of the issue in which the paper appears; however please note that they are sent by surface mail, so overseas orders may take up to 6 weeks to arrive. PDF offprints are sent to the requesting author at his/her first e-mail address on the title page of the paper, unless advised otherwise; please therefore ensure that the name, address and e-mail address of the corresponding author are clearly indicated on the manuscript title page if he or she is not the first author of the paper.

**The BJCP Annual Prize for Authors in Training**

The British Pharmacological Society awards an annual prize of £1,000 for the best paper published in BJCP during a calendar year. Those eligible will be Registrars in Clinical Pharmacology and Therapeutics (usually ST3s and above) registered for Higher Medical Training in the UK and the Republic of Ireland and those in comparable training schemes (including PhD schemes) elsewhere. Potentially eligible authors will be contacted by the Editorial Office at the end of each academic year and invited to complete an application form, giving information about the provenance of the work and the precise role played by the potential award winner. The Editors will judge all entries, but they may call for expert assistance in making their decision. Their decision is final.
Transfer to other British Pharmacological Society (BPS) journals

_Pharmacology Research & Perspectives (PR&P)_ is an open access journal jointly edited on behalf of the BPS and the American Society of Pharmacology and Experimental Therapeutics (ASPET). The BPS also publishes _British Journal of Pharmacology (BJP)_ The Editors of _BJCP_ might consider that a submitted manuscript is out of scope and more suitable for consideration by _BJP_ or _PR&P_. If so, the Editors will offer authors the opportunity to transfer their manuscript to the Editorial office of its sister journals for consideration.

**ETHICS**

Please see above and here for full guidance on all issues related to Publication Ethics.

**Informed consent**

Consent must be informed. The ethical aspects of all studies involving human subjects will be particularly noted when assessing manuscripts. The methods section should include a statement that the subjects consented to the study after full explanation of what was involved; it should indicate whether or not consent was obtained in writing.

The Methods section should contain a statement that, when applicable, explicit patient consent was obtained for the use of tissue for research. Local laws (e.g. the Human Tissue Act) should be adhered to. Where potentially relevant (e.g. functional investigations) details of the donors’ drug histories must be provided. Drug history must include any anaesthetic used for the biopsy.

**Images of, or information about, identifiable individuals**

It is the author’s responsibility to obtain consent from patients and other individuals for use of information, images, audio files, interview transcripts, and video clips from which they may be identified. To ensure we have the rights we require, please provide a signed Patient consent form in all instances. If the person is a minor, consent must be obtained from the child’s parents or
guardians.

- If the person is deceased, it is both essential and ethical that you obtain consent for use from the next of kin. If this is impractical you need to balance the need to use the photo against the risk of causing offence. In all cases ensure you obscure the identity of the deceased.

- If using older material, or for material obtained in the field, for which signed release forms are, for practical purposes, unobtainable, you will need to confirm in writing that the material in question was obtained with the person's understanding that it might be published.

**Ethics Committee Approval**

Details should be given in the methods section of the approval of the study protocol by an ethics committee or similar body and the approval number or identification code should be provided. The ethics committee that approved the protocol should be described in sufficient detail to allow the committee to be identified.

**Useful resources**

**Guidelines on Publication Ethics**

For full guidance on all aspects of Publication Ethics, please see [here](#).

**Guidelines on Reporting**

For guidance on how to enhance the quality and transparency of health research, please see [here](#)